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1 Introduction 
1.1 Tumour targeting for diagnosis and therapy 
Approximately 100 years ago Paul Ehrlich postulated the presence of “receptors” that are 
selectively expressed by pathogens or malignant tissue and that these receptors can be 
targeted using defined molecular scaffolds; a concept he termed “magic bullets” and which 
already anticipated the use of antibodies as well as small molecules as therapeutic targeting 
agents [1]. The development of monoclonal antibody technology by Köhler and Milstein in 1975 
[2] and the discovery of tumour related cell surface markers such as the epidermal growth factor 
receptor (EGFR) initiated the rational design of tumour targeting agents. Since then, a large 
number of cell surface markers with differential expression in diseased and healthy tissue have 
been identified, and different kinds of targeting agents against these markers were developed. 
Tumour targeting covers a large field of strategies including the use of small molecule inhibitors 
that act intracellular on a specific protein, like diverse kinase inhibitors. However, here the term 
is used to describe a scenario in which a ligand is used as vehicle, to deliver a bioactive 
molecule or a contrast-enhancing agent to the site of disease, enabling receptor specific 
diagnosis or therapy. This definition is valid to a large extend also for naked monoclonal 
antibodies as the Fc-part mediates biological activity through recruiting complement factors or 
immune effector cells. Antibodies are still the most frequently used targeting agents with the 
broadest range of specificities. By the generation of minimal antigen binding antibody fragments 
and the use of these fragments as building blocks, affinity probes can now be customized for 
e.g. optimal tumour retention or fast systemic clearance. Targeted materials in turn, range from 
small molecule fluorophores and toxins, to fluorescent quantum dots with a few nanometers and 
gas filled microbubbles with several micrometers in diameter. Though very different in the 
details, all targeted drug delivery as well as the growing number of molecular imaging 
applications always require: 1st a ligand that binds selectively to the molecule of interest, 2nd a 
bioactive or contrast enhancing compound, combined with suitable hardware for detection and 
3rd an optimal strategy to link both activities together.  
Subject of this work is the development of single chain antibody fusion proteins that carry an 
intrinsic “self coupling activity” mediated by an engineered enzyme tag, the characterization of 
these ligands by coupling to various substrates and analysis of their in vivo targeting properties 
by means of optical imaging. 
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1.2 Affinity probes for molecular targeting 
Several parameters have to be considered when choosing a molecule for the targeting of 
tumours. Next to high specificity for the target, to avoid cross-reactivity, the affinity of a 
compound is one essential factor. For example it has been demonstrated that for single chain 
antibody fragments (scFv), affinities in the low micromolar to nanomolar range are required for 
efficient tumour targeting in vivo [3]. Increasing the affinity to the lower picomolar level however, 
can result in a “binding site barrier” and uneven tumour penetration [4, 5]. For antibody based 
targeting agents, there is a trend to increasing valency rather than affinity [6]. The size has 
strong influence on pharmacokinetics. In general, small size results in more rapid and efficient 
penetration of the tumour mass, but also non-tumour tissues. On the other hand, the size 
determines to a large extend the circulation time of an agent. Long circulation times are usually 
desirable for therapeutic agents as they lead to longer exposure and higher overall uptake of 
the agent into the tumour tissue. In contrast, fast systemic clearance is preferable for most 
imaging applications. Here, the balance between quick measurement, a strong signal and high 
tumour to background ratio is crucial. For a probe to be cleared from the system by renal 
filtration, the molecular weight cut off is approximately 60-70 kDa. The stability of an agent also 
influences the in vivo targeting properties. Unmodified RNA aptamers for example, are rapidly 
degraded by exonucleases in the serum, making them unsuitable for in vivo applications, while 
IgG antibodies are relatively stable in serum and are in addition protected from degradation 
through their interaction with the neonatal Fc-receptor FcRn [7]. The route of excretion is 
another important factor. Small hydrophilic compounds are usually cleared via renal excretion 
[8]. Larger, less hydrophilic molecules are directed into the digestive tract via accumulation and 
break down in the liver and excretion into the bile [9]. Larger proteins, including full-length 
antibodies are degraded to a large extent in the reticulo-endothelial system (RES), mainly 
consisting of monocytes and macrophages in the lymph nodes and the spleen. These physico-
chemical characteristics of a potential targeting agent have to be considered along with aspects 
such as immunogenicity, internalisation behaviour and intracellular trafficking and a targeting 
system has to be carefully adjusted to the intended application [10].  
Today there are different classes of targeting structures available, ranging from small molecules 
to monoclonal antibodies, which are combined with a variety of effector molecules or particles. 
Folic acid is one example of a small molecule that has been used extensively for targeting 
radionuclides, chemotherapeutics, nanoparticles or fluorophores to folic acid receptor 
expressing tumours. The α from of the folic acid receptor is expressed in a variety of human 
cancers including brain, uterus, ovarian and lung cancer [11], and folic acid binds the receptor 
with high affinity (∼10-9 M) [12]. Yet, next to folic acid, there are only few more examples of small 
molecules used for tumour targeting [13, 14].  
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Peptides are an interesting class of targeting ligands. They can be deduced from natural 
receptor binding peptides or selected against diverse targets and with high affinities from large 
libraries using display technologies. Once identified, their synthesis is easy and they can be 
readily optimised and modified for conjugation due to their limited chemical complexity [15]. The 
most prominent peptide ligands used for targeting are the fibronectin derived, αvβ3 integrin 
binding RGD and cyclic RGD, the somatostatin analogues and bombesin derived peptides 
binding to the gastrin releasing peptide receptor. Peptide ligands have been conjugated to drug 
compounds, for the delivery of radio metals for imaging and therapeutic purposes, as well as 
the targeting of nanoparticles and liposomes [15, 16].  
Aptamers, DNA or RNA oligonucleotides which are selected from a large pool of sequences for 
binding to a target molecule mediated by their individual secondary structure, have developed 
into an independent class of targeting agents over the recent years [17, 18]. Similar to peptide 
ligands, aptamers can be synthesised chemically, are relatively small (20-30 kDa), can be easily 
modified and are non immunogenic. The introduction of 2'deoxy, 2'F, 2'NH3 or 2'OMe 
modifications into RNA aptamers enabled the generation of RNAse stabilised constructs that 
can be used for application in vivo. Accordingly they have been applied as targeting ligands to 
deliver radioactivity, toxic compounds, siRNAs and nanoparticles to tumour specific markers 
[19-23]. A number of natural protein ligands such as the epidermal growth factor (EGF), IL-2 
and CD30L have been evaluated as targeting agents, either as chemical conjugates or as 
fusion proteins combined with a toxic protein [24-26]. The use of these natural ligands confers 
high specificity and reduces the immunogenicity, but also raised concerns about side effects 
resulting from their biological activity. In most cases more potent monoclonal antibodies 
replaced the natural ligands in targeting approaches. In contrast, the phosphatidylserine binding 
proteins, annexinV and C2A domain of synaptotagmin I, are successfully used to probe 
apoptosis in a variety of approaches [27, 28]. 
Antibodies are the prototype of a targeting agent. Since hybridoma technology enabled the 
development of monoclonal antibodies with defined specificity, these have been used for 
therapeutic as well as diagnostic purposes. In principle, high affinity antibodies can be 
generated against any protein but also carbohydrate and lipid structures and as a result an 
unmanageable amount of studies using antibodies as targeting agents has been published. 
They are used as direct conjugates with cytotoxic compounds, for the delivery of nanoparticles 
and liposomes and as radio or fluorescent conjugates for imaging applications. Full-length 
antibodies are relatively large molecules of 150 kDa and approximate hydrodynamic diameters 
of 11 nm. The size in combination with high serum stability leads to long circulation times when 
they are administered in vivo, a feature that is considered a benefit for therapeutic constructs, 
but can be a drawback for imaging applications where high tumour to background ratios and 
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short measuring intervals are needed. A variety of antibody fragments has been developed, 
ranging from the classical Fab-fragments, over single domain antibodies to minibodies and 
multivalent constructs as illustrated in Figure 1. These antibody fragments retain their original 
antigen specificity but are reduced in size, which alters their pharmacokinetic properties. They 
also lack the effector cell or complement recruiting function of the Fc part. Except of the rare 
single domain antibodies, scFv antibodies represent the smallest form of an antibody with full 
binding activity. They consist of only the antigen binding variable domains connected via a 
peptide linker, resulting in a size of ∼28 kDa, and are used as a building block for the generation 
of formats with higher valency. ScFv are generated from existing monoclonal antibodies or they 
can be selected from v-gene repertoires using display technologies such as phage or ribosome 
display [29]. They are easily amenable to genetic manipulation and have been used for the 
generation of immunotoxins by fusion to cytotoxic proteins or engineered into formats with 
higher valency for enhanced tumour accumulation and retention. Altogether, recombinant 
antibody technology has advanced significantly in recent years and fragments with improved 
affinity, stability as well as the possibility of functional modification are expected to provide the 
basis for the next generation of antibody therapeutic and diagnostic agents [30]. 
 
 
Figure 1: A selection of different antibody formats 
Fab fragments are obtained after papain cleavage of full-length antibodies or can be expressed in a recombinant 
form. The scFv fragment is generated by linkage of the variable domains of the heavy chain and the light chain via a 
short peptide linker. Single Vh domains (dAbs) with high binding activities can be isolated from camelids and certain 
shark species but are rarely used. The scFv format serves as a building block for the generation of antibody 
fragments with higher valency, such as minibodies and diabodies. scFv can be fused with other recombinant 
proteins. Fusion to the SNAP-tag allows site-specific modification of the antibody fragment with other functional 
molecules mediated by the tag. 
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1.3 Targeted drug delivery 
Targeting ligands can be used to specifically deliver drug compounds to their desired site of 
action, thereby reducing systemic toxicity. Conventional chemotherapy is often accompanied by 
severe side effects as a result of lacking specificity of the active compound. Combining a drug 
that acts on proliferating cells, e.g. by interfering with microtubule assembly, with a ligand that 
binds a receptor overexpressed on cancer cells, adds a second step of selectivity and the local 
or intracellular release of the compound can significantly increase the efficacy of a treatment. 
Two strategies are pursued for ligand directed drug delivery. These are 1st, the direct 
conjugation of a drug compound to a targeting moiety or 2nd, the incorporation of the drug into a 
nanoparticle or polymeric carrier, which is then modified with targeting ligands. 
The amount of receptors on a targeted cell is limited. As a result, very potent compounds such 
as maytansinoid, auristatin or calicheamicin derivatives, which are generally too toxic to be used 
without targeting moiety, have to be used in the direct conjugates. Here, a payload of only few 
molecules per ligand is sufficient to induce apoptosis in the targeted cell. 
Several antibody drug conjugates (ADC) have been developed and are tested in clinical trials. 
Antigens include leukaemia markers such as CD33 and CD22 as well as solid tumour markers 
like PSMA or CD56 [31]. So far, the anti CD33-calicheamicin conjugate gemtuzumab 
ozogamicin is the only drug conjugate approved by the FDA. Peptide and small molecule 
conjugates have also been investigated but overall, the targeting and pharmacokinetic 
properties of antibodies seem to be most suitable.  
Chemotherapeutic agents such as Doxorubicin, Taxol and others are less toxic. These 
molecules have to be combined with polymeric or liposomal carriers, to deliver sufficient 
amounts into a cell via a surface receptor. Conjugates of drugs with macromolecular carriers 
can by themselves accumulate in tumours as a result of the enhanced permeability and 
retention (EPR) effect [32] and drug polymers and liposomes are intensively tested in clinical 
trials [33]. A liposomal formulation of Doxorubicin e.g. is approved for the treatment of 
metastatic breast cancer [34]. Targeting of such liposomal or polymeric compounds has great 
potential to further increase treatment efficacy through enhanced accumulation at the tumour 
and increased internalisation [35]. Full-length antibodies and peptides and also antibody 
fragments have been applied for targeting liposomal drugs to tumours [36]. Among the different 
polymers that are used for drug delivery, dendrimeric forms have gained very much attention in 
the recent years. These can be produced with homogenous size and defined number of 
functional groups for coupling of drugs or other effector molecules and targeting ligands [37]. 
Hyperbranched polyglycerol is an example of a biocompatible and versatile dendritic carrier that 
can be combined with a variety of potential effector molecules such as Doxorubicin or small 
interfering RNAs (siRNAs) [38-40]. 
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The targeted delivery siRNAs has been the subject of intensive research in the recent years. 
siRNAs allow the sequence specific knock down of complementary mRNAs and thereby precise 
manipulation of cellular signalling pathways. There are some obstacles associated with the 
systemic delivery such as the low stability of siRNAs in serum and intracellular trafficking, 
especially the endosomal escape after receptor mediated internalization. Nevertheless, several 
groups have described the successful targeted delivery and gene knock down with direct 
conjugates as well as nanoparticle based approaches [22, 41, 42]. 
 
1.4 Molecular imaging 
Targeted contrast agents are a key concept for the field of molecular imaging (MI), which is 
broadly defined as “in vivo characterization and measurement of biologic processes at the 
cellular and molecular level” [43]. 
In contrast to traditional imaging technologies such as computer tomography (CT) and magnet 
resonance imaging (MRI) that provide anatomical and physiological data, in vivo molecular 
imaging allows the detection of events underlying a certain disease based on the expression or 
presence of an associated marker. These are usually cell surface proteins and receptors that 
show a differential expression on e.g. a malignant cell or tumour associated vasculature but can 
also be an elevated enzymatic activity inside a cell or in the extracellular matrix. By using 
probes that specifically recognize such a marker, it is possible to visualize a disease non-
invasively and at an early stage of development. Thus, molecular imaging has become an 
important discipline in preclinical research, where it is used to monitor experimental treatments, 
to accelerate the screening for novel drug compounds [44] and for the establishment of more 
suitable animal models [45]. In clinical oncology MI applications are established for diagnosis 
and treatment follow up of different kinds of tumours. MI is believed to be a key in the further 
development towards personalized medicine. It will enable the early assessment of the 
molecular profile of a disease in an individual patient, e.g verification of a specific receptor that 
serves as target for a treatment.  
In principle several technologies can be used for imaging on the molecular level. There are two 
general prerequisites: 1st, a probe must be available that specifically recognizes a certain target 
and 2nd, there must be a highly sensitive detection system that allows visualization of a limited 
number of target molecules. Next to the traditional nuclear imaging techniques gamma-imaging 
(planar or SPECT) and PET, other modalities like MRI, CT, ultra sound (US) and optical imaging 
(OI) are developed further to provide information on the molecular level.  
Nuclear imaging: Positron emission tomography (PET) and single photon emission computed 
tomography (SPECT) are ideally suited for molecular imaging because of their high sensitivity 
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and accuracy. Single photon emission techniques like the planar scintigraphy and the three 
dimensional SPECT utilize gamma emitters, usually radio metals like like 99mTc which can be 
detected by a gamma camera in very low doses. They are combined with a targeting ligand by 
the attachment of a chelating agent like diethylene  triaminepentaacetic acid (DTPA) or 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) in a first step and complexing 
the chelator is with the radiometal in a second step. Radionuclides used in SPECT have a half-
life time of several hours, for example 6 h for the commonly used 99mTc. This leaves a 
reasonable time for the generation and handling of the conjugates. In contrast, most PET 
contrast agents utilize short lived positron emitting radio nuclides like 11C and 18F or 13N which 
requires an on site cyclotron and complicates the production and handling of the probes [46]. 
Protein conjugates for PET imaging frequently use 68Ga (T1/2 = 67.6 min) together with a 
chelating agent. Although both technologies in principle provide high resolution 3D images that 
allow tumour localization, PET, as it is becoming more commonly available today, is often 
preferred because of it’s higher sensitivity and possibility of accurate quantification of the 
signals [47]. SPECT in turn allows distinguishing different emission energies and could 
potentially be used to detect different tracers applied in parallel. 
All sorts of targeting ligands have been used to generate probes for nuclear molecular imaging.  
Fluorine-18-2-fluoro-2-deoxyglucose (18FDG) is the most successful and thus most commonly 
used contrast agent for PET imaging. It takes advantage of the higher metabolic activity of 
many tumour types, which goes along with a higher utilization of glucose. 18FDG is transported 
actively into the cell where it accumulates after phosphorylation by hexokinases. This way it 
provides information on a molecular level although it is not a classical targeted contrast agent. It 
is used for diagnosis and staging of patients as well as for treamtment follow-up [48] and new 
radiodiagnostic PET tracers are often evaluated based on their performance compared to FDG. 
Folic acid as an example for a “small-molecule” targeting agent has been conjugated to many 
different radionuclides. It has been used successfully for gamma and PET imaging of folate 
receptor positive tumours in pre-clinical research and has entered early clinical trials for the 
diagnosis of ovarian cancer [49, 50].  
RGD peptides targeting αvβ3 integrin conjugated with a chelating agent and complexed with 
99mTc or 111In for SPECT as well as 68Ga or 18F for PET are widely studied as tool to analyse 
angiogenesis and αvβ3 integrin expression in general [51-53] and are moving into clinical trials 
[54]. The somatostatin analogue octreotide-DTPA 111In conjugate is used routinely in the clinic 
for the diagnosis of somatostatin receptor positive neuroendocrine tumours [55, 56].  
Antibody based radiopharmaceuticals have been intensively investigated and four γ-emitting 
conjugates, targeting TAG-72, EPG-1, CEA and PSMA, were approved by the FDA in 1992-
1996. However, except the PSMA targeting Capromab pendetide, all were discontinued either 
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for economical reasons or due to insufficient performance compared to 18FDG [57]. Even if the 
FDA has approved no new, diagnostic antibody-radio conjugate since 1996, there has been an 
enormous amount of research in this field. Novel markers were identified and advances in 
antibody technology and imaging instrumentation are likely to lead to broader applicability of 
radiolabelled antibodies for molecular imaging [58]. 
Magnetic resonance imaging (MRI): MRI is a powerful imaging technique that can provide 
anatomical and functional information with high special resolution (<100 µm) and in a broad 
variety of clinical and pre-clinical settings such as cardiovascular and neuro-imaging and also in 
the detection of cancer. Contrast in MRI can be enhanced with paramagnetic materials. E.g. 
iron oxide nanoparticles in different sizes are used in functional MRI imaging [59]. As sensitivity 
of detection directly correlates with the amount of paramagnetic species and thus with the size 
of e.g. the iron oxide particle, there are some limitations for using MRI on the molecular level. 
Model calculations indicate an approximate number of 106 paramagnetic species/cell to yield 
sufficient contrast [60]. The result is that size and pharmacokinetic behaviour of a targeted 
particle have to be balanced according to the amount of available receptor. However, several 
approaches with targeted iron oxide nanoparticles have demonstrated the possibility to perform 
imaging on the molecular level using MRI. Yang et al. e.g. used 10 nm iron oxide particles, 
conjugated with either uPAR specific peptides or a single chain antibody fragment against 
EGFR and additionally labelled with a near infrared dye, to target orthotopic breast or pancreatic 
cancer. The targeted particles localized at the tumour and could be detected with MRI. They 
also found good correlations between the MRI and the signals obtained from optical imaging 
[61, 62]. Targeted MRI was also used to probe apoptosis in vivo. With iron oxide particles of 
approx. 50 nm conjugated with annexinV low levels of cardiomyocyte apoptosis could be 
detected with a 9.4 tesla device [63].  
Computer tomography: Electron dense materials can be used to enhance contrast in computer 
tomographic imaging. In particular gold nanoparticles have been investigated as vascular CT 
contrast agents [64-66]. Conjugation of antibodies to a gold nanoparticle as targeted contrast 
agent has been reported, but their functionality in vivo has not been shown jet [67]. However, 
with limitations as described for targeted MRI, CT is expected to be generally applicable for 
imaging on the cellular and molecular level. 
Ultra sound imaging: Contrast enhanced ultrasound imaging uses so called micro bubbles 
which consist of a shell of lipids, albumin or biodegradable polymers such as lactic acid/glycolic 
acid filled with a gas like air, nitrogen or perfluorocarbon. These microbubbles are used in sizes 
ranging from approximately 1 µm to 6 µm and are injected systemically for perfusion imaging. 
Microbubbles allow the conjugation with targeting ligands, which in principle makes them 
applicable for molecular imaging. Due to their large size, microbubbles cannot extravasate the 
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vascular system and molecular targeting is therefore restricted to disease markers expressed 
on endothelial cells. Targeted ultrasound imaging has been used to visualize inflammation 
associated with ischaemia-reperfusion injury, atherosclerotic disease and cardiac transplant 
rejection by using microbubbles conjugated to monoclonal antibodies against VCAM-1, ICAM-1 
or P-selectin [68-71]. VEGF-2 and αvβ3 integrin were targeted with antibody-conjugated 
microbubbles to image tumour vascularisation [72].  
Optical imaging: Optical imaging is developing rapidly as an alternative to nuclear imaging 
technologies in pre-clinical research and selected clinical applications. Compared to PET and 
SPECT it is cost effective and easy to use and it does not require specialized radiochemical 
expertise while the sensitivity of optical detection systems is comparable to or even exceeding 
PET imaging. Different optical imaging technologies have been developed including the use of 
cell lines transfected with luciferase that generates light by conversion of a luminogenic 
substrate as luciferin or cell lines stably transfected with fluorescent proteins [73]. A general 
consideration when light is used as a signal for in vivo imaging is its limited penetration depth in 
tissues. Several tissue components, mainly water, lipids and haemoglobin, absorb light at 
different wavelengths resulting in the decrease of signal intensity and autofluorescence 
generated by the tissues to be imaged. Near infrared light with wavelengths between approx. 
700-1000 nm has a very low absorption in tissue compared to blue, green or red light [74]. It is 
therefore preferably used for in vivo imaging purposes and imaging with a penetration depth of 
up to 20 cm can be theoretically performed when using 3D reconstruction algorithms of photon 
propagation as applied in fluorescence molecular tomography (FMT) [75]. Several fluorophores 
are available in the near infrared range. The most commonly used are indocyanines like Cy5.5, 
Cy7, or ICG. Quantum dots, small nanocrystals (1–10 nm) made of inorganic semiconductor 
materials and coated with a biocompatible shell, have also been used to design probes for 
optical imaging [76]. One advantage of optical imaging is that the coupling of fluorophores to a 
targeting ligand is relatively easy compared to radionuclides, where half-life is a critical point. As 
a result, a broad variety of fluorescent imaging probes has been developed against a diversity 
of target structures. The ligands used to target fluorophores to a disease specific marker are 
generally the same as those used for the nuclear imaging modalities. Peptides ligands such as 
cRGD or somatostatin analogues have been conjugated to fluorophores or quantum dots to 
detect tumours in mice [77-79]. Full-length antibodies, including the approved therapeutic 
antibodies Cetuximab and Trastuzumab were labelled with various dyes and used for tumour 
detection [80-82]. Although pharmacokinetic and biodistribution studies with radiolabeled 
ligands have shown the superior properties of antibody fragments compared to full-length 
antibodies for imaging purposes, there is only a limited number of publications describing the 
use of these fragments, Fab, scFv, diabodies or minibodies, for optical imaging. Neri et al. 
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described the influence of antibody affinity and valency on tumour targeting using scFv-
fragments modified with a near infrared dye [83]. An anti CEA Fab-fragment has been used to 
detect colon carcinoma xenografts via NIR optical imaging [84]. Due to the scattering of light in 
tissues, clinical application of OI is limited to screening of superficial tissues such as breast and 
skin. In addition to this, however, fluorescently labelled probes may have a great impact on 
established endoscopic and guided surgery procedures. Endoscopes can easily be equipped 
with a fluorescence light source and optical probes have already been used to detect small 
metastases or to more precisely define the tissue to be resected [85, 86]. OI is particularly 
interesting in pre-clinical research because of its relatively simple handling and similarity to 
nuclear imaging modalities in terms of probe design (a ligand coupled to a chelating agent to is 
not much different from one coupled to a fluorophore). It is used here on the one hand to 
analyse the pharmacokinetic properties of the drug compounds themselves, e.g. tumour 
accumulation and retention, systemic clearance and route of excretion, by labelling them with a 
fluorescent dye. On the other hand treatment effects can be analysed by OI, using target cells 
transfected with a fluorescent protein or by using fluorescent probes that indicate the presence 
of a targeted protein or cell. At the same time OI can be used for the more precise evaluation of 
treatment models as it allows matching an observed effect with e.g. tumour size, position and 
vascularisation.  
 
1.5 EGFR as target for imaging and therapy 
The EGF receptor 1 (HER, ErbB1) belongs to a family of tyrosine kinases, the ErbB family, 
consisting of 4 members (ErbB1-4). The receptor family is named after a constitutively active 
viral homologue of the chicken c-ErbB-1 (v-erbB-1), which was isolated from the avian 
erythroblastosis virus. In fact, the EGFR was the very first growth controlling cell surface protein 
to be identified. All ErbBs consist of an extracellular part that serves as binding site for a battery 
of ligands, and an intracellular part containing a kinase domain and auto-phosphorylation sites 
at the C-terminus of the receptors. ErbBs are activated by the formation of receptor dimers, 
homo- or hetero-dimers depending on the receptor, induced by binding of a ligand, that leads to 
auto-phosphorylation. Different phosphorylation patterns are possible, depending on the homo-
or heterodimer composition and the type of ligand involved in the complex. The phosphorylated 
receptor dimers are bound in a next step by phosphotyrosine binding proteins, implementing the 
cell surface signal into different cellular signalling pathways, including the Ras/Raf-, PI3K-AKT- 
and the p70S/p85S6K-pathways [87]. These pathways lead, through a complex network of 
signal processing and cross talk, to cellular responses ranging from triggering 
growth/proliferation to cell migration or differentiation. Dysregulation of this network through e.g. 
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over-expression caused by genetic amplification of receptors or mutated, constitutively active 
receptors is found in many types of cancer, leading to reduced sensitivity to apoptotic signals, 
enhanced responsiveness to growth signals and angiogenesis [88]. EGFR over-expression has 
been found in many epithelial cancers including head and neck [89], colon [90], lung [91], 
pancreas [92], prostate [93] and also gliomas [94], where it is often associated with aggressive 
growth, resistance to conventional chemotherapy and poor prognosis [95]. The elevated 
expression on different kinds of tumours, combined with the low expression in normal tissue, 
makes EGFR an attractive diagnostic and therapeutic target [96]. The monoclonal antibody 
Cetuximab (Erbitux) for example binds to the extracellular domain III of EGFR, thereby inhibiting 
ligand binding and receptor activation [97]. It is used to treat cancers of the head and neck and 
metastatic colorectal cancer [98, 99]. Small molecule thyrosine kinase inhibitors such as 
gefitinib and erlotinib also act specifically on EGFR and are used for the treatment of advanced 
pancreatic cancer and non-small cell lung cancer [100]. Despite their high specificity, the clinical 
efficacy of these 1st generation EGFR targeted drugs is relatively poor [101] and many 
approaches investigate the delivery of cytotoxic compounds in form of immunotoxins or nano-
carrier based systems to actively induce apoptosis in the targeted cells. As for each of the 
mentioned cancer types only subpopulations of patients show elevated expression, the non 
invasive assessment of the EGFR status of a patient using molecular imaging, could have 
significant impact on planning EGFR directed treatment. This is in particular true for targeted 
delivery or radiotherapy approaches, were the amount of receptor on the cell surface directly 
correlates with the amount of effector molecules that can be transported to or into the cells. 
Accordingly, a number of EGFR targeted imaging probes have been developed for detection 
with nuclear or optical imaging technologies. Koyama and Co-workers labelled Cetuximab with 
a near infrared dye and showed that it is possible to discriminate EGFR+ and EGFR- tumours in 
nude mice [102]. Tolmachev et al. used a 7 kDa affibody molecule labelled with 111In-DOTA for 
gamma camera imaging [103]. The use of a dimeric form of the same affibody molecule, 
labelled with a NIR dye for optical imaging of EGFR has recently been reported [104]. Molecular 
PET imaging of EGFR also showed, at least for full-length antibodies, that the signal obtained in 
vivo does not necessarily reflect the actual number of EGF-receptors expressed on a tumour 
and that additional factors like vascularisation have to be taken into account [105]. 
Nevertheless, EGFR remains one of the best characterized molecular targets for the treatment 
of cancer and imaging probes directed against EGFR may greatly improve existing and 
upcoming “targeted therapies”. 
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1.6 Bioconjugation of proteins with effector molecules 
All previously described targeting approaches, either for diagnostic or therapeutic purposes, 
have in common, that they use a targeting moiety combined with an effector moiety or complex 
that have to be linked together in a way that is not affecting their respective activity. Drug 
delivery systems often require in addition linker structures that release the drug within the 
targeted cells, while being stable in the blood stream. Coupling of the ligand to a particle or the 
modification with a small molecule is an essential step in most targeting approaches. Proteins 
and peptides naturally contain four different reactive groups that are used for chemical 
conjugation. These are amino, sulfhydryl and carboxyl groups and carbonyl groups in 
glycoproteins. Modification of these groups can be performed with a variety of available cross-
linking reagents, but it is usually random and this can alter or disrupt protein activity. Full-length 
antibodies are commonly modified with NHS-esters (reacting with amino groups) or maleimides 
(reacting with sulfhydryls) with a high degree of modification and without affecting the antigen 
binding activity. However, in this case, only about ¼ of the protein is involved in antigen binding, 
while the rest is available for modification. In contrast, the small single chain antibody fragments 
often do not tolerate chemical modification as they consist only of the antigen binding variable 
domains and the majority of residues is involved in antigen recognition or is essential for the 
protein structure. This fact is likely to be one reason why scFv, despite their excellent properties 
in terms of affinity, specificity and flexibility regarding the type of antigen, are not jet as 
intensively used as mAbs and peptides. While peptides can usually be coupled via their N- or C-
terminus, for more complex protein ligands it is highly desirable to find methods that allow 
directed and specific coupling via predefined residues, so that the modification does not alter 
the protein activity. Site-specific coupling can be realized e.g. by the introduction of cysteine 
residues or unnatural amino acids with unique reactive groups. C-terminal cysteine residues are 
the most commonly applied method for modification of scFv but the effect of site-specific 
coupling via engineered cysteins could also be demonstrated with a full-length antibody drug 
conjugate. The therapeutic index of an auristatin E conjugate could be improved significantly, 
after directed coupling, compared to a randomly modified construct [106]. The introduction of 
non-natural amino acids is an elegant method that allows site modification but it requires the 
use of engineered bacterial strains for the production of the respective ligands [107]. Tag based 
systems are available for the labelling of proteins with fluorophores including the Halo-tag and 
the lumio-tag, but the use of these systems for in vivo applications is limited [108, 109]. Several 
enzyme based modification methods have recently been developed, describing a new concept 
for bio-conjugation of recombinant proteins. Here a protein is equipped genetically with a short 
peptide tag that serves as an acceptor site for a label transferred by an enzyme that is added to 
the coupling reaction. Examples include the biotin holoenzyme synthetase, sortases and the Sfp 
Introduction   
 
13 
phosphopantetheinyl transferase [110-112] that modifies protein tags derived from the acyl 
carrier protein (ACP). Nevertheless, most of the existing coupling methods are either unspecific 
or laborious or they are not broadly applicable and alternative, more convenient coupling 
methods are still needed.  
 
1.7 SNAP-tag technology 
The SNAP-tag is an engineered version of the human DNA repair enzyme O(6)-alkylguanine 
DNA alkyltransferase (AGT) [113]. AGT scans the DNA for alkyl adducts on guanine and thymin 
bases and removes them by transfer to cysteine145 in its active site through a nucleophilic 
substitution reaction. This reaction renders the enzyme inactive and it is subsequently degraded 
[114]. AGT is important in maintaining DNA integrity on the one hand and it is investigated as 
target for cancer therapy on the other as its expression can render tumours resistant to 
chemotherapy with DNA alkylating agents [115]. The SNAP-tag was developed as a tool for 
specific protein labelling by displaying mutant libraries of AGT on phage and selection towards 
higher reactivity with para-substituted O(6)-benzylguanine (BG) derivatives [116]. In additional 
approaches mutations were introduced to reduce the DNA binding affinity and size of AGT [117] 
and to remove two non-essential cysteines. A version of AGT with all mutations combined (15 in 
total) was then subjected to additional rounds of phage display selection combining random 
mutagenesis in a first step with a saturation mutagenesis approach in two distinct regions 
affecting the activity and specificity. The resulting engineered version of AGT displayed a 52 
fold increased activity towards BG compared to the wild type enzyme, with a second order rate 
constant for the reaction with BG-fluorescein of 2.8x104 M-1 s-1 [113]. 
Through genetic fusion, this protein tag can be used to modify a fusion partner with substrates 
that contain BG. The protein is connected with the para-substituted benzyl via a stable thioether 
bond while releasing free guanine. The technology has been applied in a variety of experimental 
systems, ranging from in-cell labelling of tagged proteins with cell permeable BG-fluorophore 
derivatives to immobilization of proteins on BG-modified chip surfaces [118-120]. The SNAP-tag 
is approximately 20 kDa in size and it can be used to generate N- or C-terminal fusion proteins. 
As the coupling reaction is very efficient, and BG (BC) building blocks can be used to chemically 
modify many different substrates in an independent reaction, the SNAP-tag as well as the more 
recently described, O(2) benzylcytosine reactive CLIP tag [121] are an interesting alternative to 
conventional bioconjugate techniques. 
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1.8 Aims and Objectives 
The aim of this work was to explore the SNAP-tag technology in combination with recombinant 
antibody fragments and other protein ligands and to develop it as a tool for the site-specific 
modification of these molecules. Single chain antibody fragments (scFv) have great potential as 
targeting agents, however, the modification of scFv by chemical means, e.g. for conjugation 
with an effector molecule, can be challenging. Most of the existing techniques lack specificity 
and impair the activity of the scFv. The SNAP-tag is capable of binding substrates that are 
modified with benzylguanine (BG) and a broad range of substances can be modified with BG 
easily with chemical methods. Combining the targeting properties of scFv with the coupling 
potential of the SNAP-tag results in an antibody format that should have wide applicability in the 
field of molecular targeting.  
In order to investigate the potential of this technology, as a first step, a series of fusion proteins 
consisting of a single chain antibody fragment or a natural protein ligand and the SNAP-tag 
should be engineered and their expression in mammalian cells should be established. A proof 
of principle was previously shown with a fusion protein consisting of the anti CD30 single chain 
fragment Ki4 and the SNAP-tag (Markus Ribbert, Fraunhofer IME). The binding activity of the 
new fusion proteins and the activity of the tag should be analysed by using fluorescent BG-
derivatives. Bioconjugates consisting of a targeting ligand in combination with liposomes or 
polymeric drug carriers, quantum dots and other nanoparticles have been intensively 
investigated in the resent years and efficient bioconjugation techniques are essential for their 
development. In this regard, the capability of the scFvSNAP-tag fusion proteins to couple to BG 
modified, fluorescent silica nanobeads should be tested to evaluate their potential for the 
targeting of such nanoparticles.  
In a similar fashion, bio-conjugation to fluorescently labelled, Doxorubicin loaded polyglycerol 
dendrimers should be investigated as model system of a targeted polymeric drug conjugate. 
Coupling via BG, binding and internalisation properties should be analysed.  
Optical imaging has developed as a sensitive, cost effective and easily accessible method in 
pre-clinical research and allows, by the use of fluorescently labelled ligands, the detection of 
specific molecules e.g. on a tumour surface. It further allows evaluating targeting probes for 
their potential use in other imaging modalities. As a major focus of this work, methods for the in 
vivo optical imaging in small animals should be developed, applying the SNAP-tag fusion 
proteins as active targeting ligands. To this end, a stable GFP expressing cell line should be 
generated and used for the establishment of a subcutaneous pancreatic carcinoma xenograft 
model in athymic nude mice. Optical imaging technology provides a means of analysing the 
pharmacokinetics and biodistribution of a fluorescently labelled probe with a limited number of 
animals. Here, the technology should be used to determine the in vivo targeting properties of 
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the EGF-receptor specific antibody fragment 425(scFv) in combination with the SNAP-tag. This 
information will be valuable also for predicting the pharmacokinetics of other single chain 
antibody based constructs. Depending on the course of the experiments, the properties of 
scFvSNAP fusion proteins as optical imaging probes will be compared to those of the full-length 
antibody C225 that has been used in several published optical imaging studies. As a result, the 
present studies should provide a basis for the further use of scFvSNAP fusion proteins for 
molecular imaging and targeted drug delivery. 
 
 
 
Figure 2: Schematic structure and workflow of the present work 
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2 Materials and Methods 
2.1 Materials 
2.1.1 Equipment 
All equipment and devices used in this work are listed below. 
Table 1: Equipment 
Device Model (Manufacturer) 
Cell counter  Casy1 (Schärfe System) 
Cell washer Dade Serocent (Baxter) 
Centrifuges  MicrofugeR, Avanti J-30I Centrifuge, Allegra 6KR Centrifuge (Beckman) 
Biofuge Pico (Heraeus Instruments) 
Picofuge (Stratagene) 
Rotilabo Centrigue with Butterfly-Rotor (Roth, Karlsruhe, Germany) 
Cryo sections Cryostat CM 3050 (Leica) 
DNA sequencing  ABI Prism 3700 Capillary-Sequencer (Perkin- Elmer) 
ELISA plate reader  Elisareader ELx808 (Bio-TEK) 
Flow cytometry  FACScalibur (Becton Dickinson),  
FACS-Vantage with DiVa option (Becton Dickinson) 
FPLC Äkta Purifier (Amersham Pharmacia Biotech) 
Gelelectrophoresis and 
Electroblotting 
Mini Protean III gel chamber (BioRad Laboratories, Inc.), Protein Gel-
Apparatus and supplies Mini PROTEAN II™ (BioRad), Gel Air Dryer 
(BioRad), Mini Trans-Blot Cell (bioRad) 
Incubators  Thermomixer compact (Eppendorf AG), Incubator (Heraeus Instruments) 
Incubators (Cell culture) Binder 
Laminar flow  Hera Safe HS12 (Kendro) 
Liquid handling  Pipetman P (Gilson), 
Multichannel Pipettes (Eppendorf) 
Microscopes TCS SP5 confocal laser microscope (Leica), DMIL inverted microscope 
with mecury fluorescence light source (Leica), DM2000 (Leica) 
PCR-Cylers  Primus 96 Plus (MWG-Biotech),  
Programmable Thermal Controller PTC-200™ (MJ Research Inc.) 
Photometer  Biophotometer (Eppendorf), 
Software  AIDA image analyzer (Raytest) 
Sonication Sonication probe UW2070 (Bandelin 
Electronic)  
Micro tip MS72 
Transiluminator  Molecular Imager Gel Doc XR System (BioRad) 
Vortex  Vortex-Genie 2 (Scientific Industries Inc.) 
Waterbaths F32, TW20 (Julabo) 
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2.1.2 Chemicals and Consumables 
Unless otherwise noted consumables and chemicals were purchased from the following 
companies: Dickinson Bioscience (Franklin Lakes, USA), Bio-chrom (Berlin), BioRad 
(München), Biozym (Oldendorf), Clontech (Heidelberg), Corning Inc. (Schiphol-Rijk, Nederland), 
Covalys (Witterswil, Switzerland), Cytogen (Obermörlen), Dharmacon (Lafayette, USA), 
Eppendorf (Hamburg), Greiner (Solingen), Hampton Research (Aliso Viejo), Hewlett-Packard 
(München), Invitrogen (Eggenstein), Kodak (Stuttgart), KMF Laborchemie (St. Augustin), 
Millipore (Eschborn), MWG-Biotech (Ebersberg), New England Biolabs (NEB; Schwalbach), 
Nunc (Wiesbaden), Novagen (Madison, USA), Pall Filtron (Northborough, USA), Perkin-Elmer 
(Applied Biosystems, Foster City, USA), Pierce (Rockford), Promega (Mannheim), Qiagen 
(Hilden), Roche Molecular Biochemicals (Mannheim), Roth (Karlsruhe), Sarstedt (Nümbrecht),  
Schott-Glaswerke GmbH (Neufahrn/San Diego), Serva (Heidelberg), Sigma (Deisenhofen), 
Starlab (Ahrensburg), Whatman (Maidstone, England), VWR (Darmstadt). 
 
2.1.3 Buffers and Media 
Standard buffer and stock solutions were prepared according to standard procedures using de-
ionized water. Solutions were sterilized by autoclaving (25 min/ 121 °C/ 2 bar). Heat-sensitive 
components, such as antibiotics, were prepared as stock solutions, filter-sterilized (0.2 μm) and 
added to the medium/buffer after cooling below 50 °C. The composition of all commonly used 
buffers is listed below. 
 
Table 2: Buffers and Media 
Buffer Composition Concentration  
10x PBS (pH 7.4) NaCl  
KCl  
Na2HPO4 x 12H2O  
KH2PO4  
1.37  
27  
81  
15  
M  
mM  
mM  
mM  
1x PBST (pH 7.4) 1x PBS  
Tween 20  
 
0.05 
 
% (w/v) 
TGS (pH 8.3) Tris-HCl (pH 8.3)  
Glycine   
SDS  
25  
192  
0.1  
mM  
mM  
% (w/v)  
TAE (pH 8.2) Tris  
Glacial acetic acid  
EDTA  
40  
5.7  
10  
mM  
% (v/v)  
mM  
5x OrangeG Loading  OrangeG  
Glycerol  
0.01  
30  
in 1x TAE  
% (w/v)  
% (v/v)  
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Table 2: Buffers and Media 
Buffer Composition Concentration  
Coomassie Staining Solution  Coomassie bb. G-250  
Methanol  
Glacial acetic acid  
0.25  
50  
9  
%(w/v)  
% (v/v)  
% (v/v)  
Coomassie Destaining 
Solution  
Methanol  
Glacial acetic acid  
10  
10  
% (v/v)  
% (v/v)  
5x (reducing) Protein Loading 
Buffer  
Tris-HCl (pH 6.8)  
Glycerol  
SDS  
Bromphenolblue  
(ß-Mercaptoethanol) 
62.5  
30  
4  
0.05  
10  
mM  
% (v/v)  
% (w/v)  
% (w/v)  
% (v/v)  
SDS PAGE gel (separating 
gel)  
Acrylamide/Bisacrylamide 
(30/1)  
Tris-HCl (pH 8.8)  
SDS (10 %, w/v)  
TEMED  
APS (20%, w/v)  
 
x  
375  
0.1  
0.1  
0.1  
 
mL  
mM  
% (w/v)  
% (v/v)  
% (v/v)  
SDS PAGE gel  
(stacking gel) 
Acrylamid/Bisacrylamide (30/1)  
Tris-HCl (pH 6.8)  
SDS  
TEMED  
APS  
5  
150  
0.1  
0.1  
0.1  
% (w/v)  
mM  
% (m/v)  
% (v/v)  
% (v/v)  
4x binding buffer (Ni-NTA 
purification, pH 8) 
Na2HPO4 
NaCl 
Imidazol 
200 
1.2 
40 
mM 
M 
mM 
Wash buffer (Ni-NTA 
purification, pH 8) 
Na2HPO4 
NaCl 
Imidazol 
50 
300 
40 
mM 
mM 
mM 
Elution buffer (Ni-NTA 
purification, pH 8) 
Na2HPO4 
NaCl 
Imidazol 
50 
300 
500 
mM 
mM 
mM 
Media    
LB (pH 7) NaCl 
Peptone 
Yeast extract 
1 
1 
0,5 
% (w/v) 
% (w/v) 
% (w/v) 
SOC Peptone 
Yeast extract 
NaCl 
KCl 
MgCl2 
MgSO4 
glucose 
2% 
0,5% 
10 
25 
10 
10 
20 
(w/v) 
(w/v) 
mM 
mM 
mM 
mM 
mM 
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2.1.4 Kits and enzymes 
Unless otherwise stated restriction enzymes for molecular cloning were purchased from NEB or 
Roche Molecular Biochemicals or Promega and used according to the manufacturer’s 
recommendations. The following kits were used: 
 
Table 3: Reaction Kits 
Application  Kit Company 
DNA extraction from agarose gels NucleoSpin ExtractII Macherey-Nagel 
Plasmid DNA preparation 
 
NucleoSpin Plasmid  
Plasmid Mini Kit 
QIAfilter Plasmid Maxi Kit  
Macherey-Nagel  
Qiagen 
Qiagen 
Cell viability Cell Proliferation Kit II (XTT) Roche Applied Sciences 
 
2.1.5 Antibodies 
Penta His AlexaFluor 488 (Qiagen): monoclonal mouse antibody directed against the penta 
histidine motive, conjugated with the fluorescent dye AlexaFluor 488 
 
Anti-His (C-term) (Invitrogen): monoclonal mouse antibody directed against C-terminal 6 
histidine tag with free COOH group. 
 
Goat anti mouse HRPO/AP (Sigma): polyclonal goat antibody directed against the Fc part of 
mouse IgG conjugated with horseradish peroxidase or alkaline phosphatase. 
 
Anti human Ig (H+L) (Fab’)2 FITC (Chemicon): sheep polyclonal F(ab’)2 antibody fragment 
directed against human Ig heavy and light chain, conjugated with fluorescein-isothiocyanate. 
 
2.1.6 Engineered protein tags and source plasmids 
The SNAP-tag, CLIP-Tag and ACP-Tag sequences were amplified from the following source 
plasmids provided by Covalys-AG: pSS26m (SNAP-tag), pCLIP10m (CLIP-tag) and pASwt 
(ACP-tag). The SNAP-tag reacts and binds covalently substrates containing benzyl-guanine. 
CLIP tag is derived from the SNAP-tag and reacts specifically with benzyl-cytosin. The ACP-tag 
serves as acceptor site for groups derivatized with co-enzyme A. The reaction is catalysed by 
the enzyme ACP-synthase. Primers for the amplification of the tag sequences are listed in 
Table 4. 
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2.1.7 Synthetic oligonucleotides 
Synthetic oligonucleotides were purchased from MWG-Biotech in standard quality. 
All DNA oligonucleotides used in this work are listed below. 
 
Table 4: Oligonucleotides used for cloning and DNA sequencing 
Nr. Oligo name  Sequence 
Cloning/sequencing 
1 EGF-NotI_rev  GTA TGC GGC CGC GCG CAG TTC CCA CCA C 
2 EGF-SfiI_for ATA CGG CCC AGC CGG CCA ATA GTG ACT CTG AAT GTC CC 
3 3_-SNAP26m_Blp ATT CGT GCT CAG CGC CCA GCC CAG GCT TGC CC 
4 5_-Xba_Snap26m ACT CTA GAA TGG ACA AAG ACT GCG 
5 Snap-NotI_for ATACGCGGCCGCATGGACAAAGACTGCGAAATG 
6 Snap-XbaI_rev GTA TTC TAG AGC CCA GCC CAG GCT TGC CC 
7 Hai-XbaI_for ATA CTC TAG AAT GGC CGA GGT GCA ACT GC 
8 Hai-BlpI_rev GTA TGC TCA GCC CGT TTG ATC TCG AGT TCT G 
9 XbaI-clip_for ATA CTC TAG AAT GGA CAA AGA CTG CG 
10 clip-BlpI_rev GTA TGC TCA GCA CCC AGC CCA GGC TTG C 
11 XbaI-acp_for ATA CTC TAG AAT GAG CAC TAT CGA AG 
12 acp-BlpI_rev GTA TGC TCA GCC GCC TGG TGG CCG TTG A 
Sequencing 
13 T7-promoter AAT ACG ACT CAC TAT AG 
14 T7-Terminator  GCT AGT TAT TGC TCA GCG G 
15 Hinter-His for CCA ACA GCT GGC CCT CGC AGA CAG 
16 pMS Seq_rev2 CCA GAT GGA CGC GGC CAC CC 
 
2.1.8 Bacterial strains 
The following Escherichia coli strains were used for selection and amplification of plasmid DNA: 
 
XL-1 blue: supE44 hsdR17 recA1 endA1 gyr A46 thi relA1 lacF’ [pro AB+ lacIq lacZΔM15 
Tn10(tetr)] (Stratagene) 
 
DH5a: F- φ80 lacZΔM15 Δ(lacZYA-argF) U169 recA1 endA1 hsdR17(rk-, mk+) phoA supE44thi-1 
gyrA96 relA1 tonA (resistant to phage T1) (Invitrogen) 
 
 
 
 
Materials and Methods   
 
21 
2.1.9 Mammalian cell lines 
 
Table 5: Mammalian cell lines and their characteristics 
Cell line Characteristics Reference 
HEK 293T  Human embryonic kidney cells, transfected with SV40 large T antigen. The 
large T antigen promotes replication of e.g. plasmids containing a SV40 origin 
of replication by interaction with the host DNA polymerase alpha, resulting in 
very high copy numbers of the plasmid in the host cell thus increasing 
expression levels of recombinant protein 
ATCC Nr.  
CRL-11268 
L540 Human Hodgkin lymphoma derived cell line with strong CD30 expression and 
T-cell origin 
DSMZ Nr. 
ACC 72 
U937 Human cell line derived from histiocytic lymphoma, basal CD64 expression, 
increased expression after stimulation with e.g. IFNγ 
ATCC Nr. 
CRL-1593.2 
L3.6pl Human pancreatic carcinoma cell line, selected in the mouse for higher 
metastatic potential, EGFR+ 
Bruns.et al. 
[122] 
L3.6pl-GFP L3.6pl cells, transfected with maxGFP (from Pontellina plumata)  
A431 Human epithelial carcinoma cell line with high EGFR expression ATCC Nr. 
CRL-1555 
CHO-K1 
 
Chinese hamster ovary cells, adherent subclone 
 
DSMZ Nr. 
ACC 110 
 
2.1.10 Antibody fragments and protein ligands 
The following table gives an overview over the antibody fragments and ligands used in this 
work. 
 
Table 6: Origin and specificity of antibody fragments and protein ligands 
Antibody/ligand  specificity  origin/specification 
425(scFv) human EGF receptor, extracellular 
domain III (no mouse cross reactivity) 
derived from the mouse 
monoclonal antibody 425, 
blocks binding of EGF 
hEGF human EGF receptor  human cDNA 
H22(scFv) human CD64  humanized monoclonal antibody H22 
Ki4(scFv)  human CD30 mouse monoclonal antibody Ki4 
CD30L human CD30 human cDNA 
 
2.1.11 Plasmid vectors 
The pMS vectors used for the expression of antibody or protein-ligand fusion proteins in 
mammalian cells are a derivative of the pSecTag2 vector (Invitrogen) containing an IRES eGFP 
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sequence as reporter gene for successful transfection and expression of the target protein 
[123]. The CMV promotor drives expression and proteins are expressed with an N-terminal Igκ-
leader sequence, which mediates their secretion into the culture supernatant. The coding 
sequences are introduced by SfiI/NotI restriction either upstream or downstream of the 
SNAP26m gene. The vectors for N- and C-terminal fusions are illustrated in Figure 3. 
 
 
Figure 3: Schematic of pMS vectors for the production of fusion proteins with C-terminal or N-terminal SNAP-tag 
Analogous vectors were cloned for the generation of CLIP-Tag and ACP-tag fusions. Fusion partners are inserted via 
the SfiI/NotI restriction sites. Protein expression is driven by the CMV promotor and proteins are secreted into the 
culture supernatant by the Igκ-leader sequence. The C-terminal 6His-tag facilitates purification of the recombinant 
proteins from the supernatant by immobilized metal ion affinity chromatography (IMAC). Reporter eGFP expression is 
mediated by an internal ribosomal entry site (IRES). The plasmids contain a Zeozin-resistance gene (SV40 promotor) 
for the selection of transfected cells and an ampicillin resistance gene as well as a ColE1 origin of replication for 
selection and propagation in E.coli. 
 
2.2 Methods 
2.2.1 Molecular cloning and DNA work 
Molecular cloning of DNA fragments was performed using standard procedures as described by 
Sambrook et al. (2001). 
2.2.1.1 Polymerase chain reaction (PCR) 
PCR reactions for the amplification of DNA fragments to be used in cloning were prepared with 
the Pfu DNA polymerase (Phusion high fidelity polymerase, Finzymes), according to 
manufacturer’s recommendations in a volume of 25-50 µl. Pfu polymerases have a 3’-5’ 
exonuclease (proof reading) function which results in higher accuracy during amplification. 
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Table 7: PCR program for the amplification of DNA fragments for cloning 
 
 
 
 
 
 
 
Primers were annealed at 55° C or the optimal annealing temperature was determined 
empirically using a temperature gradient PCR. In some cases DMSO was added to a final 
concentration of 1% (v/v) to improve the specificity of the amplification. The amplified products 
were separated by agarose gel electrophoresis and isolated from the gel for subsequent cloning 
steps. Colony PCRs were performed to verify a specific insert in selected bacterial colonies 
after transformation with plasmid DNA. Whenever possible a combination of a primer binding 
specifically in the insert of interest and a primer binding in the vector backbone were used. 
A standard PCR reaction was prepared as follows: 
 
Table 8: Colony PCR reaction mix 
Component Concentration 
10x Taq DNA Polymerase Buffer 1x 
dNTP-Mix 10mM (2,5 mM/dNTP) 0,2 mM 
MgCl2 1 mM 
5´-Primer 5-10 pmol 
3´-Primer 5-10 pmol 
Taq-DNA Polymerase 1 U 
Aqua bidest. (sterile) ad 25 µl 
 
Bacterial colonies were grown overnight and transferred partly to the PCR reaction mix.  
 
Table 9: Program Colony PCR 
 
 
 
 
 
 
 
Step Temperature (C°) Time 
Initial denaturation 95 5 min 
Denaturation 95 30 sec  
Annealing Tp Primer 30 sec  
Elongation 72 45-90 sec 30x 
Final elongation 72 5 min 
Step Temerature (°C) Time 
Initial denaturation 96 10 min 
Denaturation 96 30 sec  
 
30x 
Annealing Tp Primer 30 sec 
Elongation 72 45 sec-1.5 min 
Final elongation 72 5 min 
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2.2.1.2 Endonuclease restriction of DNA 
Restriction endonucleases and the respective buffers were purchased from New England 
Biolabs (NEB). The restriction of DNA was performed following the manufacturer’s instructions. 
The double restrictions of DNA with two different endonucleases were carried out following the 
manufacturer’s instructions in the most appropriate buffer system. 
2.2.1.3 Dephosphorylation of restricted vectors  
If necessary, the restricted plasmid DNA was dephosphorylated using the shrimp alkaline 
phophatase (SAP, Roche Diagnostics GmbH) following the manufacturer’s instructions. SAP 
catalyzes the 5’-phosphate of DNA and prevents religation of the plasmid after restriction. 
2.2.1.4 Ligation of restricted DNA 
The ligation of two restricted DNA fragments was performed using T4-DNA-Ligase (NEB) 
following the manufacturer’s instructions in a total volume of 15-25 µl. Ligation reactions were 
performed with a 3 times molar excess of DNA insert to plasmid vector. 
2.2.1.5 Determination of DNA concentration 
DNA concentrations were determined by analytical agarose gelelectrophoresis and comparison 
of the ethidium bromide fluorescence intensity of the respective DNA band with marker DNA of 
known concentration (2-Log DNA Ladder, NEB) at 302 nm. Alternatively concentrations were 
measured spectrophotometrically at 260 nm using an Eppendorf Biophotometer. 
2.2.1.6 Analytical and preparative agarose gel electrophoresis of DNA 
Size and concentration of plasmids, restriction fragments and PCR products were analysed 
agarose gel electrophoresis using 0.8-2 % (w/v) agarose gel containing 3 µg/mL 
ethidiumbromide at a field strength of 4-5 V/cm. The electrophoresis was performed following 
the protocol of Sambrook et al. (2001) in 1xTAE buffer. 1 µg of 2-Log DNA Ladder (NEB) served 
as size and concentration standard. Separated DNA fragments were visualized using a Gel Doc 
XR System (BioRad) at a wavelength of 302 nm. Plasmids, PCR products or restricted DNA 
were isolated from agarose gels by UV transillumination and excision of the respective band 
using a clean scalpel. The DNA was purified using the QIAquick gel extraction kit (Qiagen, 
Hilden, Germany) following the manufacturer’s instructions.  
2.2.1.7 Culturing of bacteria 
Recombinant E. coli clones were selected on LB-agar plates containing 100 µg/mL ampicillin by 
overnight incubation at 37 °C. 
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For the preparation of plasmid DNA from E.coli or the preparation of glycerol stocks, bacteria 
were grown overnight in 5 mL LB medium with amplicillin at 37 °C and 225 rpm on a shaker. 
Glycerol stocks were made by mixing 750 µl of overnight culture with 250 µl of a 60 % (v/v) 
solution of sterile glycerol and freezing at -80 °C. 
2.2.1.8 Transformation of bacteria with plasmid DNA 
Competent E.coli DH5a or XL-1 blue cells were prepared according to Sambrook et al. (2001) 
and transformed with plasmid DNA using a heat shock transformation protocol. Competent cells 
were mixed with 5-15 µl of ligation reaction mix and incubated for 30 min on ice followed by 
incubation at 42 °C for 90 sec. 800 µl SOC medium was added followed by incubation for 30 
min at 37 °C on a shaker. Transformed bacteria were plated on LB ampicillin agar plates (100 
μg ampicillin/mL) and incubated at 37 °C for 16 h. Recombinant bacteria were analysed either 
by Colony-PCR (2.2.1.1) or plasmid preparation and control digest to verify the insert. All newly 
cloned constructs were finally verified by DNA sequencing (2.2.1.10). 
2.2.1.9 Preparation of plasmid DNA from E. coli 
For plasmid DNA preparation overnight cultures of bacterial clones were grown (2.2.1.7) and 
DNA was isolated from bacterial pellets using the QIAprep Spin Miniprep Kit (Qiagen) following 
the manufacturer’s instructions. For the isolation of larger amounts of plasmid DNA a 
maxipreparation of plasmid DNA was carried out using the Qiagen Plasmid Midiprep Kit 
(Qiagen) following the manufacturer’s instructions.  
2.2.1.10 DNA sequencing  
Sequence analysis was performed at the Fraunhofer IME sequencing facility using an “ABI 
Prism 3700” Capillary-Sequencer (Applied Biosystems) with BigDye™ cycle sequencing 
terminator chemistry and the Applied Biosystems Sequencing Analysis Program. Resulting 
sequences were analyzed with DNA-Star software. 
 
2.2.2 Cell culture 
2.2.2.1 Culture conditions for mammalian cells 
All cell lines were cultured in RPMI1640 (Gibco) supplemented with 10 % (v/v) heat-inactivated 
fetal bovine serum (FBS) (Gibco), 50 µg/mL penicillin and 50 µg/mL streptomycin. The cells 
were maintained at 37 °C in a humidified atmosphere of 5 % CO2.  
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2.2.2.2 Production of Recombinant Proteins in HEK-293T Cells 
HEK-293T cells were transfected with RotiFect (Carl Roth GmbH) using 1 µg of plasmid DNA  
(2.2.1.9) and 3 µL RotiFect, according to the manufacturer’s instructions. The expression and 
binding activity of each SNAP-tag fusion protein was tested 3 days after transfection by flow 
cytometry using the culture supernatant and an anti-His-tag Alexa488 antibody conjugate 
(Qiagen) to detect the his tag of cell bound, recombinant protein. SNAP-tag activity was tested 
by staining 10 µL of supernatant with a BG derivative modified with carboxyfluorescein (Vista-
Green, Covalys) followed by sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-
PAGE, 2.2.3.1) and visualization of the labelled protein with a UV-transilluminator. High 
producing cultures were obtained by selecting cells with high reporter eGFP production either 
microscopically or by fluorescence activated cell sorting. Established transfected cultures were 
grown in RPMI 1640 medium supplemented with 10 % (v/v) heat inactivated fetal bovine serum 
(FBS), 50 µg/mL penicillin, 100 µg/mL streptomycin, 2 mM l-glutamine and 100 µg/mL Zeocin 
(all components were obtained from Invitrogen). For the production of larger amounts of protein, 
triple flasks were inoculated and 500-1000 mL supernatant was collected for purification. 
 
2.2.3 Protein biochemical methods 
2.2.3.1 Polyacrylamid gel electrophoresis 
Discontinuous SDS-PAA gel electrophoresis (SDS-PAGE) according to Laemmli et al. was 
performed to separate and visualize recombinant proteins. The protein samples were mixed 
with 1/10 volume of 10x SDS-PAGE loading buffer and denatured for 5 minutes at 98 °C. Gels 
were run under constant voltage in a „Mini-Protean III“-protein gel electrophoresis chamber 
(BioRad). All proteins were visualized by staining of the gel with Coomassie Brilliant blue G250. 
Fluorescently labelled proteins were visualized in the gel using a UV transilluminator (BioRad) 
or the Maestro imaging system (CRi).  
2.2.3.2 Purification of SNAP-tag fusion proteins  
His-tagged proteins were purified from cell-free supernatants by Ni–NTA metal affinity 
chromatography. Small volumes were purified in batch procedure, using 1-5ml of supernatant 
equilibrated with 4x buffer (200 mM NaH2PO4, 1.2 M NaCl, 40 mM imidazol, pH 8). The 
supernatant was incubated with 30-150µl of Ni-NTA agarose (Qiagen) for 30 min at room 
temperature and washed 3x with phosphate-buffered saline (PBS) by centrifugation before 
elution of bound protein with 1x buffer containing 500mM imidazol. Larger volumes of 
supernatant were purified on an Äkta FLPC system with a 5 mL Ni-NTA Superflow cartridge 
(Qiagen) after equilibration with 4x buffer. After a washing step with 1x buffer containing 40mM 
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imidazol and elution with 500 mM imidazol, proteins were dialyzed against PBS containing 1 
mM dithioerythritol (DTE). The concentration of the eluted protein ranged between 300-800 
µg/mL. If necessary, samples were concentrated to 0.5-1 mg/mL with a 5 kDa MWCO VivaSpin 
Column (Sigma-Aldrich). Ectoine was added as cryo-preservative to a final concentration of 50 
mM and aliquots were stored at -20 °C until further use. 
2.2.3.3 Protein labelling with BG derivatives of organic fluorophores or biotin 
Purified SNAP-tag fusion proteins (2.2.3.2) were conjugated with the BG-modified dyes 
(Covalys AG, Witterswil) by incubation in the dark with 1.5-3 fold molar excess of dye for 2 h at 
room temperature or overnight at 4°C. Residual dye was removed by gel filtration 
chromatography using PD10 columns (GE) or dialysis. Alternatively, after small scale batch 
purification, the conjugation was performed with the protein still bound to the Ni-NTA resin with 
one bed volume of a 2 µM dye solution in 1x Ni-NTA wash buffer (300 mM NaCl, 50 mM sodium 
phosphate, pH 7.5). The labelled protein was eluted with 500 mM imidazole after washing away 
residual dye. Stained proteins were visualized after separation by SDS-PAGE with either a UV 
transilluminator (BioRad Gel Doc XR) or with a CRi Maestro imaging system using blue, red and 
near-infrared filter sets. Biotinylation was performed by incubating the fusion proteins with a 2-5 
fold molar excess of BG-Biotin using the same procedure as described for fluorophores. All BG-
dye derivatives used in this work are listed in Table 10. 
2.2.3.4 Labelling of Cetuximab with Dy 747-NHS 
The Cetuximab antibody (C225) was labelled with the 747 dye as an NHS ester derivative (Dy-
747-NHS, Dyomics). 1,4 mg C225 in 1 mL PBS were reacted with six equivalents Dy-747-NHS 
in DMSO (5 nmol/µl) for 2h at room temperature. Residual dye was removed with a PD10 
column and the labelled antibody was concentrated to 5 mg/mL. The dye to protein ratio for this 
probe was 2.7. 
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2.2.3.5 Photometrical measurement of coupling efficiencies 
Coupling efficiencies were determined by measuring the absorbance in a solution of the 
conjugated protein at 280 nm and the excitation wavelength of the respective dye using a photo 
spectrometer. To ensure accurate measurements the protein solution was diluted so that 
absorption values of 0.1-1 were obtained. The molar extinction coefficient of the dye was used 
to calculate the dye to protein ratio using the following equations. The label concentration can 
be calculated as follows: 
 
 
 
Label conc. =
Ax nm × dilution factor
extinction coeff. dye
 
 
 
Protein conc. =
A280nm - Ax × F( )( )× dilution factor
extinction coeff. of the fusion protein
 
 
 
The degree of labelling is calculated with: 
 
 
 
% labeling =
label conc.
protein conc.
×100 
 
 
Ax is the absorption at wavelength x while x is the wavelength were the molar extinction 
coefficient of the respective dye is determined. F is the absorbance of the dye at 280 nm as a 
proportion of its absorbance at x. This factor is given along with the extinction coefficient on the 
data-sheets of the dye and is listed in Table 10. 
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Table 10: BG-derivatives of fluorescent dyes and their characteristics 
Compound (dye) Excitation/Emission 
(nm) 
Molar extinction 
coefficient (M-1 cm-1) 
F* MW 
(g/mol) 
Comments 
BG-green (ATTO488) 506/528 90000 (506 nm) 0.198  In vitro 
BG-vista green 
(fluorescein) 
500/524 n.a. n.a. 628.59 In vitro 
BG-505 (Dy-505) 504/532 n.a. n.a. 679.12 In vitro, cell 
permeable 
BG-TMR-star 
(tetramethylrhodamine) 
554/580 n.a. n.a. 713.61 In vitro, cell 
permeable 
BG-AlexaFluor647 
(AlexaFluor647) 
652/670 239000 (650 nm) 0.13  In vitro + in 
vivo 
BG-747 (Dy-747) 752/763 200000 (752 nm) 0.081 942.32 In vivo 
BG-782 (Dy-782) 784/789 94969 (784 nm) 0.128 1131.25 In vivo 
CT-488 (ATTO488) 506/526 90000 (506 nm) 0.198  In vitro 
CoA 488 502/522 90000 (506 nm) 0.198  In vitro 
(F*=absorbance of the dye at 280 nm as a proportion of its absorbance at x, see 2.2.3.5, n.a.=not available) 
 
Table 11: Physicochemical properties of different SNAP-tag fusion proteins 
Fusion protein Molar ext. coefficient at 
280nm (M-1 cm-1)* 
Aa Theoretical 
pI 
MW 
425(scFv)SNAP 78185 464 5,94 49.8 
Ki4(scFv)SNAP 75205 470 6.76 50.3 
H22(scFv)SNAP 79675 468 6.32 50.3 
SNAP-EGF 39920 257 5.85 27,8 
SNAP-CD30L 42900 376 6.52 41.2 
SNAP 21095 180 6.15 19.3 
(* determined with ProtParam-tool assuming all cysteine residues appear as half cystines) 
 
2.2.3.6 Serum stability assay with 425(scFv)SNAP 
To analyse the serum stability of the scFvSNAP fusion proteins 425(scFv)SNAP was labelled 
with BG-505 and incubated at a concentration of 67 µg/mL in PBS with 50% normal mouse 
serum for 48 h. Samples each containing 500 ng of labelled antibody were removed at various 
time points and frozen immediately at -20°C. The binding activity on A431 cells of all samples 
was then analysed by flow cytometry. Binding was normalized against the untreated probe and 
A431 cells without label. A one-phase exponential decay curve fit (GraphPad, Prism) was used 
to determine the serum half-life of the scFvSNAP.  
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2.2.4 Flow cytometry 
2.2.4.1 FACS based binding analysis of recombinant proteins 
Flow cytometry was performed with a FACScalibur (Backton Dickinson). For a standard FACS 
based binding analysis 4x105 target or control cells were incubated with 15-1500 ng/mL of 
purified protein in PBS or 300-500 µl culture supernatant of transfected cells (2.2.2.2) for 20 min 
on ice. Unbound protein was removed by 1-2 wash cycles with PBS (cell washer, Dade 
Serocent). Protein bound to the cell surface was detected either through a directly labelled 
SNAP-tag or by incubation with mouse monoclonal antibody α−penta His Alexa488 (Qiagen). 
Directly labelled SNAP-tag fusion proteins were analysed depending on the emission 
wavelength of the respective dye in FL-1, FL-2 or FL-4. SNAP-tag fusion proteins labelled with a 
near infrared (NIR) dye were detected with anti−penta His Alexa488, because the FACS-Calibur 
is not equipped for detection of NIR light. The C225 chimeric full-length antibody was detected 
with Anti human Ig (H+L) (Fab’)2 FITC (Chemicon). 
2.2.4.2 Competition analysis with SNAP-EGF and 425(scFv)SNAP 
Competition experiments were carried out by pre-incubation of the target cells with increasing 
concentrations of unlabelled competitor. A fixed amount of labelled ligand (2.2.3.3) was added 
after 20-30 min when equilibrium binding could be expected and inhibition of binding was 
determined by plotting the median, relative fluorescence intensity against the concentration of 
competitor (logarithmic). Data were normalized with the untreated cells as 0 % binding and the 
labelled probe without competitor as 100 % binding. A sigmoidal dose response curve fit was 
used to calculate EC50 values with GraphPad software (Prism). 
2.2.4.3 FACS analysis of scFvSNAP-tag - nanoparticle conjugates 
scFv-SNAP conjugates with either silica-nanoparticles or polyglycerol dendrimers were 
analysed by flow cytometry to verify the coupling and to test the binding activity of the 
respective ligands after the coupling procedure.  
Ki4(scFv)SNAP or 425(scFv)SNAP were conjugated to PG-Doxorubicin dendrimers containing 
or not benzyl-guanine and/or indocarbocyanine (ICC) or indotricarbocyanine (ITCC) and 1 µg of 
protein was used to analyse the binding on L540 and L3.6pl control cells. ICC is measured in 
the FL-2 fluorescence channel and a small percentage of the ITCC fluorescence can be 
measured in FL-4. A fluorescence shift in FL-2 or FL-4 was used as read out for specific 
binding. Binding of Ki4(scFv)SNAP or 425(scFv)SNAP conjugated silica nanobeads was 
analysed by incubation of L540 or A431 cells with 20-60 µl of beads suspension corresponding 
to 2-6 µg of protein in the initial reaction mixture (2.2.6.1). The carboxyrhodamine fluorescence 
of the beads was measured in FL-2. 
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2.2.4.4 Transfection of L3.6pl with maxGFP and selection of a stable GFP expressing 
cells  
L3.6pl cells were transfected with the plasmid pSecTag-maxGFP provided by I. Neef. The 
Igκ−leader was removed in this vector to facilitate accumulation of GFP in the cytoplasm of the 
transfected cells. 1x105 L3.6pl cells were seeded in a 12well plate and transfected with 1 µg 
plasmid DNA using 2µl Rotifect lipofection reagent (Carl-Roth GmbH) following the 
manufacturer’s protocol. The transfected cells were then cultured under Zeozin selection 
pressure for 2 weeks. After the initial selection with Zeozin cells with strong GFP expression 
were enriched by selecting the brightest 10 % - 2 % via fluorescence activated cell sorting with 
a FACS-Vantage with DiVa option (BD-Bioscience). The sorted cells were cultured in R10 
medium without Zeozin and the enrichment procedure was repeated several times. The 
transfected cells were tested for their EGFR expression using 425(scFv)SNAP labelled with 
AlexaFluor647. Single cell sorting was performed to generate a clonal L3.6pl-GFP cell line but 
did not result in viable clones. 
 
2.2.5 Cofocal microscopy 
All images were taken with a LEICA confocal microscope (TCS SP5) equipped with the 
following lasers: 458 nm, 488 nm, 561 nm and 633 nm. Cells were prepared as described 
above for flow cytometry. The cells were resuspended in 30 µl PBS and 10 µl of the cell 
suspension was incubated for 5 min with 2 µl of a 1:100 diluted Draq5 solution (Biostatus) to 
counter stain the nucleus. 
 
2.2.6 Coupling of SNAP-tag fusion proteins to “nano-sized” particles 
2.2.6.1 Coupling SNAP-tag fusion proteins to luminescent silica beads 
Spherical silica nanobeads labelled with carboxyrhodamine were used to demonstrate the 
feasibility of coupling the SNAP-tagged antibodies. The particles were provided by Dr. Carsten 
Gellermann (Fraunhofer Institut für Silicatforschung, ISC). They were prepared using a modified 
Stöber synthesis method and had an average diameter of 90 nm [124]. Amine functions were 
introduced at the bead surface using bifunctional aminosilane. The average number of amino 
functionalities on the bead surface was determined with the fluorescamine test and adjusted to 
~320 functions per bead as described [125]. To facilitate benzylguanine coupling, the beads 
were dispersed in dimethylformamide (DMF) and incubated with a 60 fold molar excess of BG-
GLA-NHS (Covalys) over amino-groups for 3 h at room temperature. The beads were washed 
three times with PBS (pH 7.4) and dispersed in the same buffer. For coupling beads where 
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dispersed in RPMI containing 10 % (v/v) FCS and 0.1 % (v/v) Tween 20 (R10-T) and sonicated 
to disrupt aggregates. Approximately 0.2 nmol of BG-beads was incubated with 50 µg Ki4-
SNAP (1 nmol) in 100 µl R10-T for 2 h at room temperature. Coupled beads were washed 4 
times with R10-T, dispersed in 200 µl RPMI-10% FCS and 60 µL of the bead preparation was 
used for analysis by flow cytometry and confocal microscopy. To block SNAP-tag mediated 
coupling Ki4-SNAP was incubated beforehand with a three fold molar excess of 
bromothenylpteridine (BTP, Covalys) for 1 h at room temperature. 
2.2.6.2 Coupling of SNAP-tag fusion proteins to Polyglycerol-Doxorubicin Conjugates 
BG functionalized Doxorubicin (Doxo) conjugated polyglycerol (PG) dendrimers were provided 
by a collaboration partner (Dr. M. Calderon, Institute for Chemistry and Biochemistry, AG-Haag, 
Freie Universität Berlin). These particles, without benzyl guanine modification, had been tested 
in a mouse model of ovarian carcinoma and displayed better anti tumour activity compared to 
free Doxorubicin. The particles are approximately 10 nm in size and contain an average of 3 
Doxorubicin equivalents per particle, conjugated via an acid sensitive bond, which is stable at 
pH7, but rapidly releases the drug at pH5. Different conjugates were provided:  
1. PG-Doxo: containing Doxorubicin conjugated to the hyperbranched polyglycerol.  
2. PG-Doxo-BG: with approx. two benzyl guanine groups per particle. 
3. PG-Doxo-ITCC/ICC: containing one equivalent of indotricarbocyanin (ITCC) or 
indocarbocyanine (ICC). 
4. PG-Doxo-ITCC/ICC-BG: containing two equivalents BG and one equivalent ITCC or ICC. A 
schematic illustration of the different dendrimer conjugates is shown in Figure 4. 
In order to couple the PG-Doxo particles with SNAP-tag fusion proteins, they were solubilised in 
PBS containing up to 8% (v/v) DMSO (in case of ITCC containing samples) to a final 
concentration of 0.2 -0.4 nmol/µl. ICC containing particles were solubilised without addition of 
DMSO. Both components were mixed in various ratios and incubated for 1-2 h at room 
temperature. Coupling efficiency was measured indirectly by staining unreacted SNAP-tag in 
the coupling mix with BG-green. The samples were then analysed by SDS-PAGE and BG-
green, Doxorubicin and ITCC/ICC fluorescence were visualized with the CRi-Maestro system. 
Signals were quantified with AIDA densitometry software (Raytest). Coupling specificity was 
additionally tested by flow cytometry and confocal microscopy.  
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Figure 4: Schematic illustration of different polyglycerol–Doxorubicin conjugates 
The polyglycerol (PG) dendrimers are 10 kDa in size with 10% amine loading. Three equivalents of a (6-
maleimidocaproyl) hydrazone derivative of Doxorubicin (Doxo-EMCH) are conjugated to yield a pH sensitive pro-
drug. One equivalent of Indotricarbocyanine (ITCC) or Indocarbocyanine (ICC, not shown) is conjugated to allow 
detection of the particles via fluorescence light. Two benzylguanine residues per particle facilitate coupling of SNAP-
tag fusion proteins. 1) PG-Doxo, 2) PG-Doxo-BG, 3) PG-Doxo-ITCC, 4) PG-Doxo-ITCC-BG. Illustrations were kindly 
provided by Dr. M. Calderon. 
 
2.2.7 Cell viability assay with polyglycerol-Doxorubicin conjugates 
The toxocity of the PG-Doxorubicin conjugates was determined using the Cell Proliferation Kit II 
(Roche) according to manufacturer's instructions. Cells were seeded with 1x104 cells/well in 96 
well plates in 50 µl of a 1:3 mixture of conditioned and fresh medium. Samples were prepared 
with a SNAP-tag to BG ratio of 1.2-1.5 in the conjugation reaction and serially diluted in a 
separate plate before addition to the cells 16 h after seeding. Assays were analysed after 
additional 48 h by measuring the absorbance at 450 nm and 650 nm. Untreated cells and cells 
incubated with 100 µg/mL Zeocin served as 100 % viability and 0 % viability controls. All 
samples were measured in triplicate. Delta 450/650 was used to determine IC50 values for each 
sample with GraphPad Prism using the log of concentrations and a sigmoid dose response 
curve fit. 
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2.2.8 Coupling of oligonucleotides to SNAP-tag fusion proteins 
As an additional class of substrate molecules, oligonucleotides, DNA oligos as well as synthetic 
siRNA molecules, were modified with BG. Nucleotides were ordered from Dharmacon with a 3’ 
or 5’ N6-group or sulfhydryl-group, which was modified with BG-GLA-NHS or BG-maleimide 
(Covalys-AG). Maleimide coupling required reduction of protection group disulfides with 100 mM 
DTT followed by a purification step (EtOH precipitation or gel filtration) to remove residual DTT 
(A. Hussein). The BG-compounds were dissolved in dry N, N-dimethylformamide (DMF, puriss., 
over molecular sieve, Sigma-Aldrich) and reactions were performed with a 30-50 fold molar 
excess of BG-linker to nucleotide. Nucleotides were purified by ethanol precipitation by adding 
one volume of H2O, 1/10 volume of 3 M sodium acetate and three volumes of EtOH (98%) and 
incubation at -80 °C for min. 30 min, followed by resuspension of the RNA pellet in 40-50 µl 
PBS and gel filtration spin column purification (Centri Spin 10, Princeton Separations). A typical 
reaction was performed with 1 nmol of siRNA in 10 µl PBS and 10 µl BG-GLA-NHS in DMF for 4 
h at 25 °C. Modified nucleotides were coupled to SNAP-tag containing proteins in 5:1 molar 
ratio for 2 h at RT. Coupling efficiency was analysed by SDS-PAGE on the basis of the size 
difference of approx. 12 kDa. 
The F9 DNA oligo, modified with BG-GLA-NHS, as well as streptavidin, chemically modified with 
a complementary DNA oligo, were provided by a collaboration partner (Prof. Niemeyer, 
Chemical-Biology, TU-Dortmund). For analysis by flow cytometry and confocal microscopy, 20 
µg Ki4(scFv)SNAP was incubated with a 5,6 fold excess of modified F9 DNA oligo for 1 h at RT 
and over night at 4 °C. Binding was detected by incubation of L540 cells with 1 µg of conjugate 
(4x105 cells, 20 min on ice) followed by incubation with streptavidin/biotin-Atto647 (20 min on 
ice) following the procedure described for FACS experiments (2.2.4.1) 
 
2.2.9 In vivo imaging methods 
2.2.9.1 Mouse strains and housing and maintenance of animals  
Athymic BALBc nu/nu mice (Charles River GmbH) were used for all animal experiments. Mice 
were housed in the “Institut für Versuchstierkunde” of the university hospital, Aachen or in the 
aminal facility of the Fraunhofer IME during the imaging experiments. All animal experiments 
were performed in accordance with the institutional guidelines for animal testing and with 
permission form the ethical committee. 
2.2.9.2 L3.6pl cells and the subcutaneous L3.6pl-GFP tumour model 
The generation of the L3.6pl cells was described by Bruns et.al [122]. Briefly a fast growing 
variant (FG) was selected from the pancreatic carcinoma cell line COLO 357. After isolation of 
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the L3.3 cell line from FG in vivo, these cells were implanted into the pancreas of nude mice 
and hepatic metastases were harvested and re-implanted into the pancreas. This cycle was 
repeated 3 times to yield the cell line L3.6pl (pl for pancreas-liver) with significantly increased 
metastatic potential. The authors report an increased expression of the pro-angiogenic 
molecules basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and 
interleukin 8 (IL-8). The increased invasiveness and motility of this cell line was associated with 
an increased expression of matrix metalloproteinase 9 (MMP9) and decreased expression of E-
cadherin. 
L3.6pl cell are epidermal growth factor receptor 1 (EGFR, Her1) positive and targeting of the 
receptor has been reported in vitro and in vivo. For the purpose of whole body in vivo imaging 
and as an easy method to monitor experimental therapy, the cells were transfected with 
maxGFP (2.2.4.4). 
To establish subcutaneous tumours, initially, approximately 2x106 L3.6pl-GFP cells in 50 µl PBS 
were injected on the left or right upper leg. Therefore the cells were trypsinised shortly, de-
attached completely using a cell scraper and washed 2x with PBS. The cell pellet was 
resuspended in PBS to a final concentration of 4x107 cells/mL. In later experiments the amount 
of cells was decreased to 1x105 cells/injection to obtain a slower and more controlled tumour 
growth and smaller tumours. Tumours established within 5 to 7 days after injection of the cells.  
2.2.9.3 Handling of mice and anaesthesia 
Prior to the injection of tumour cells or imaging probes the aminals were anesthetised by 
intramuscular administration of 75 mg/kg Ketamin – 10 mg/kg Xylazin. The intramuscular 
administration leads to rapid sedation of the animals while the applied dose of anaesthetic 
allows handling of the mice for up to 40 minutes. Tumour cells were injected subcutaneously as 
described (2.2.8.2) using an insulin syringe with a 0.3 mm x 8 mm needle. The fluorescent 
probes were administered retro-orbital in the left, right or both eyes with volumes of usually 40-
50 µl but not exceeding 80 µl/injection. Samples were broad to room temperature before 
injection. Before and after image acquisition anaesthetized mice were kept on an electric 
blanket at 37°C. 
2.2.9.4 Competitive binding analysis in vivo 
To proof the specificity of the 425(scFv)SNAP imaging probe, mice were injected with a 20 fold 
excess of unlabelled probe 3-5 min prior to the injection of the BG-747 labelled sample. 
0.5 nmol corresponding to 25 µg of labelled 425(scFv)SNAP were used. Accordingly 10 nmol 
(500 µg) of unlabelled antibody in a volume of 125 µl were injected slowly to prevent 
accumulation on the injection site. 
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2.2.9.5 In vivo optical imaging instrumentation 
In vivo optical imaging was performed with three different imaging systems. The LI-COR Pearl 
imager is a laser based system which was provided by LI-COR for a 1 week test period and was 
used for a limited number of early experiments. The CRi-Maestro system has a Xenon light 
source and allows measurements through the complete visible and near infrared light spectrum 
by applying different filter sets. One set of mice was imaged with a VisEn FMT system in parallel 
to the acquisition with the Maestro system in order to obtain 3D images of the tumours. 
2.2.9.6 CRi-Maestro imaging system: general settings and image acquisition 
Whole mouse images were taken with stage height and illumination setting 1b. For optimal 
detection of the imaging probes different exposure times, 1000 ms and 3000 ms, were usually 
applied at all time points in the mice that were injected with 1 nmol of probe. 5000 ms cube 
pictures were acquired at later time points to detect very low residual signal and in the 
experiments were 0.5 nmol of probe were used. The GFP signal derived from the transfected 
tumour cells was acquired with 200 ms to 500 ms. Depending on the imaging probe different 
excitation and emission filters were used. Table 12 gives an overview over the filters and the 
wavelengths used for image acquisition. As for the AlexaFluor 647 dye the optimal yellow filter 
was available only in later experiments, in most experiments the red filter set was used and the 
range of wavelength to be used for acquiring an optimal signal was determined empirically 
using the pure dye spotted on a cardboard and scanning the emission range in 10 nm steps.  
Before injection of the imaging probes, mice were anaesthetised with Ketamin/Xylazin as 
described (2.2.8.3) and the “pre-treatment” or “-1” pictures were made. For each mouse dorsal 
view pictures were acquired in white light with 50 ms exposure time, followed by the cube 
images for the different dyes to be detected. Cube images were either acquired separately for 
the individual dyes or a single cube was acquired for the different wavelengths using the multi 
filter acquisition tool. “0 min”, “10 min” and “30 min” pictures were taken subsequently after 
injection of the probes, when possible. Further images were then acquired after 10 h, 24 h, 48 h 
and 72 h. Mice were sacrificed after the last measurement and organs were dissected for 
histological analysis. 
 
 
 
 
 
 
 
Materials and Methods   
 
37 
Table 12: CRi-Maestro filter sets and acquisition settings 
Filter set Excitation filter Emission filter Acquisition settings 
Blue 455 nm (435 to 480 nm) 490-nm longpass 500 to 720 nm in 10-nm steps 
Yellow 595 nm (576 to 621 nm) 635-nm longpass 630 to 800 nm in 10-nm steps 
Red 635 nm (616 to 661 nm) 675-nm longpass 670 to 900 nm in 10-nm steps 
Deep red 661 nm (641 to 681 nm) 700-nm longpass 700 to 950 nm in 10-nm steps 
Near 
infrared 
704 nm (684 to 729 nm) 745-nm longpass 740 to 950 nm in 10-nm steps 
 
2.2.9.7 Maestro Software and image processing 
The first step to unmix the different dye spectra from a cube image is the definition of a spectral 
library that is used to identify and discriminate the individual spectra in the acquired images. 
Spectra were defined for each dye either with the pure dye spotted on cardboard or a control 
mouse was injected subcutaneously with small amount of imaging probe and an image with 
optimal exposure time was taken with the appropriate filter settings. Spectra must be defined in 
optimally exposed areas. Recording a spectrum e.g. in overexposed areas leads to erroneous 
results after unmixing. The same cube structure (filters and acquisition range) as for the images 
to be unmixed has to be used. The background signal as well as the mGFP spectrum from the 
tumour was defined in the cube images of the mice before injection of the probes. Following the 
so defined spectral library was used to unmix all image cubes from an individual mouse. The 
component images displaying the targeted signal or the non targeted control were used to 
define tumour to background ratios (TBRs) by drawing a region of interest (ROI) around the 
tumour and a larger area on the back representing average background signal. The average 
signal/pixel values for the region of interest were used to calculate the ratios. 
2.2.9.8 LICOR Pearl imaging system: Settings and image acquisition 
The LI-COR Pearl imager is equipped with a 600 nm and a 785 nm laser. Pictures were 
acquired at white light, 700 nm and 800 nm. The pearl system takes these pictures 
automatically and displays overlay images with optimal contrast directly after scanning the 
mouse. Signals were quantified with Pearl Cam Software in the 700 nm and 800 nm pictures 
and tumour to background ratios were built analogously to the Maestro system. 
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2.2.9.9 Fluorescence molecular tomography (FMT) system: Settings and image 
acquisition 
The VisEn FMT system was used to obtain 3D pictures of the tumours and to validate the data 
measured with the Maestro system. The measurements were conducted in the University 
Hospital Aachen, Institute for Biomedical Technology in the Department of Experimental 
Molecular Imaging (Prof. Dr. Kießling). Images were acquired with Pro-Sense 750 settings 
under isoflurane anaesthesia. In most cases, 2D and 3D scans were performed. 
2.2.9.10 Statistical analysis 
All of the data are given as means ± SD of n independent measurements. Statistical analysis of 
mouse experiments was performed with a Mann-Whitney test using GraphPad Prism 
(GraphPad Software). Statistical significance was assigned for P values < 0.05. 
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3 Results 
3.1 Cloning, expression and characterization of ligand-tag 
fusion proteins 
3.1.1 Cloning of antibody fragment and protein ligands fusion proteins 
Initially fusion proteins with the native (SfiI+) SNAP-tag sequence were cloned into the pMS 
vector system (2.1.11) by inserting the XbaI/BlpI restricted SNAP-tag sequence at the N-
terminus or the C-terminus of the respective ligand. To facilitate direct cut and paste cloning 
the internal SfiI restriction site was later removed from the tag sequence by "splicing by 
overlab extention"-PCR (Bianca Schulte, Diploma thesis) and following cloning procedures 
were performed by inserting the SfiI/NotI restricted ligand sequences into the vectors 
illustrated in Figure 3. 425(scFv) and EGF were genetically fused to the CLIP-Tag and ACP-
Tag sequences to test if these alternative tags can be equally used for site-specific labelling. 
Figure 5 illustrates the composition of the different constructs exemplarily for 425(scFv) and 
EGF. The first SNAP tag fusion protein, Ki4(scFv)SNAP was cloned by Dr. M. Ribbert in our 
lab. It contains a GGGSG linker sequence between the single chain antibody and the SNAP-
tag. This linker was not used in other constructs because the activity of both components is 
not impaired by a direct fusion. 
 
 
Figure 5: Expression cassettes of 425(scFv) and EGF based fusion proteins 
The coding sequences for the ligands are introduced using SfiI/NotI either upstream or downstream of the 
SNAP26m (CLIP or ACP) gene. An internal SfiI site in SNAP26m was deleted in a 2nd generation of vectors. The 
fusion proteins are secreted into the culture supernatant of transfected cells via an Ig-κ-leader sequence and can 
be purified via the C-terminal His-tag. Transfected cells can be selected based on their eGFP fluorescence. 
 
 
Results   
 
40
3.1.2 Expression and purification of tagged proteins 
A variety of scFvs and protein ligand fusions was cloned and produced in 293T cells. A 
selection of expressed and functionally tested constructs is shown in Table 13. 
Ki4(scFv)SNAP and SNAP-EGF expression was also assessed in CHO-K1 cells. Active 
protein could be purified from the culture supernatant but more intensive selection and 
screening was required and expression levels as achieved with the 293T cells were not 
reached (data not shown). The fusion proteins were purified from the culture supernatant in a 
single step by IMAC (2.2.3.2). The procedure resulted in protein preparations of 85-90 % 
purity. The purity was measured densitometrically in a coomassie stained polyacrylamide-
gel. High expression levels were observed for most of the fusion proteins, e.g. up to 17.5 
mg/L culture supernatant for 425(scFv)SNAP, and 5-10 mg/L for most others (Table 13). The 
SNAP-tag was active irrespective of the position in the fusion protein. The single chain 
antibodies were used in the C-terminal position, in accordance with other fusion proteins 
based on these ligands. In contrast, the ligands CD30L and EGF were functional only with 
the SNAP-tag at the N-terminal position. CLIP-Tag and ACP-tag constructs were tested for 
tag reactivity and binding activity in a small scale and were not studied in more detail after 
their principle functionality had been confirmed (Figure 8). 
 
Table 13: Ligands with SNAP, CLIP or ACP-tag expressed in 293T cells (nd=not determined) 
Construct  
 
Specificity Tag position Expression yield 
(293T) 
Application /comments 
425(scFv)SNAP EGF receptor C-terminal >15 mg/mL In vivo optical imaging 
425(scFv)CLIP EGF receptor C-terminal nd In vitro 
425(scFv)ACP EGF receptor C-terminal nd In vitro 
SNAP-EGF EGF receptor N-terminal >10 mg/mL In vivo optical imaging 
EGF-SNAP EGF receptor C-terminal nd Minimal binding activity 
CLIP-EGF EGF receptor N-terminal nd In vitro 
ACP-EGF EGF receptor N-terminal nd In vitro 
425(scFv)-SNAP-425(scFv) EGF receptor N+C-term. nd No SNAP-tag activity 
H22(scFv)SNAP CD64  C-terminal >8 mg/mL In vitro 
SNAP-CD30L CD30 N-terminal 5 mg/mL In vitro 
Ki4(scFv)SNAP (M.R.) CD30 C-terminal >10 mg/mL In vivo optical imaging 
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3.1.3 Storage and serum stability of SNAP-tag fusion proteins 
Stability was not tested in detail for every fusion protein. However, Ki4(scFv)SNAP showed 
no significant loss of binding activity or SNAP-tag activity when concentrated at ~1 mg/mL 
and stored at 4°C for 4 weeks. In contrast, ligands diluted to less than ~100 μg/mL in PBS 
rapidly lost their binding activity (2-3 days). All the constructs were tested after at least 6 
months of storage at -20°C and were found to be still active (binding as well as SNAP-tag 
activity). Precipitation was observed in some cases, when proteins were concentrated to >4 
mg/mL (H22SNAP, 425(scFv)SNAP). 
The serum stability was tested exemplarily for 425(scFv)SNAP labelled with BG-505 by 
incubation in 50% normal mouse serum over a period of 48 h (2.2.3.6). Remaining binding 
activity was analysed by flow cytometry and the median fluorescence intensities that were 
obtained with each sample were plotted against the incubation time. The serum half life time 
determined in this assay was 11.5 h.  
 
3.1.4 Labelling of SNAP fusion proteins with organic fluorophores  
The tagged proteins were labelled with different fluorophores depending on their final 
application. For binding analysis by flow cytometry or confocal microscopy BG-green and 
BG-AlexaFluor647 were used preferentially. For in vivo imaging the near infrared dye BG-
747 turned out to be the most suitable, BG-782 and AlexaFluor647 were used in earlier in 
vivo experiments. The labelling reaction was usually very efficient and yielded 90-100 % 
labelled protein after overnight incubation at 4 °C with a 1.5-2 fold molar excess of dye over 
protein. Higher dye to protein ratios did not have a strong impact on the labelling efficiency. 
Figure 6 shows a selection of SNAP-tag proteins with different fluorescent labels. The 
functionality of the CLIP and ACP fusion proteins was assessed by small-scale purification 
(900 µl supernatant) and staining with CT-488 or CoA-488 + ACP-synthase. A gel picture of 
the stained 425(scFv) and EGF fusions is shown in Figure 8, together with the verification of 
binding activity by flow cytometry. 
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Figure 6: Purified SNAP-tag fusion proteins labelled with different fluorophores (1) 425(scFv)SNAP-782; (2) Ki4(scFv)SNAP-VistaGreen; (3) SNAP-EGF-AlexaFluor647; (4) SNAP-CD30L-505 
(glycosylation leads to band broadening and an increase in size); (5) H22(scFv)SNAP-TMRstar. Approximately 1 
μg of labelled protein (2.2.3.3) was separated by SDS-PAGE (2.2.3.1) and visualized with a CRi Maestro Imaging 
System (right) and then stained with coomassie brilliant blue (left). Different dye spectra were unmixed using 
Maestro software. 
3.1.5 Binding activity of fluorescently labelled SNAP fusion proteins 
The binding activity of the recombinant proteins was analysed by flow cytometry. Ligands 
were labelled with a suitable dye and tested each on a positive cell line and a cell line not 
expressing the target receptor as a control. The CD30 specific probes Ki4(scFv)SNAP 
labelled with BG-AlexaFluor647 and SNAP-CD30L labelled with vista green both showed 
strong and specific binding on L540 cells while no binding is observed on the control cells 
(Figure 7). For Ki4SNAP-AlexaFluor647 concentration dependent binding is shown. The 
EGFR specific probes 425(scFv)SNAP and SNAP-EGF were tested on A431 cells which 
express a high number of EGFR. Both show good binding to these target cells but not to 
control cells. As different fluorophores were used, the fluorescence intensities are not 
comparable between the constructs. The antibody H22(scFv)SNAP labelled with BG-green 
binds to CD64 positive U937 cells; only minimal background staining is observed on L540 
cells (Figure 7). 
 
3.1.6 Labelling and binding of CLIP/ACP fusion proteins 
425(scFv)CLIP and EGF-CLIP as well as 425(scFv)-ACP and ACP-EGF were cloned and 
produced in 293T cells. Both, CLIP-tag and ACP-tag were active after batch purification from 
the supernatant (2.2.3.2) as N-terminal as well as C-terminal fusion and could be labelled 
successfully with BC-488 or CoA-488 (Figure 8 A). Binding activity on EGFR+ A431 cells 
could be confirmed and no binding was observed on L540 control cells (Figure 8 B+C). The 
amounts of fusion protein used for FACS analysis were not determined beforehand and may 
therefore differ significantly. Accordingly, the observed fluorescence intensities do not 
correlate directly with binding activity. 
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Figure 7: FACS analysis of several SNAP fusion proteins labelled with different fluorophores 
SNAP-tag fusion proteins were purified from the supernatant of transfected HEK293T cells (2.2.3.2) and labelled 
with different BG-modified fluorophores (2.2.3.3). Target or control cells were incubated with approximately 1 µg 
of labelled protein (or as indicated) for 20 min on ice, washed with PBS and analysed with a FACS-Calibur flow 
cytometer (Backton Dickinson) (2.2.4.1). (A) The CD30 specific probes Ki4(scFv)SNAP labelled with BG-
AlexaFluor647 and SNAP-CD30L labelled with BG-vista green. Increasing concentrations of Ki4SNAP-
AlexaFluor647 (15-1500 ng/ml) were used. (B) The EGFR specific fusion proteins, 425(scFv)SNAP labelled with 
BG-505 and SNAP-EGF labelled with BG-vista green. Binding on EGFR positive A431 cells and EGFR negative 
cells is shown. C) CD64 positive U937 cells and CD64 negative L540 cells after incubation with BG-green labelled 
H22(scFv)SNAP. Due to the different dyes used, the signal intensities are not directly comparable. 
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Figure 8: Binding analysis with 425(scFv)CLIP/ACP-488 and CLIP/ACP-EGF-488 on target and control cells 
A) shows an SDS-PAGE analysis (2.2.3.1) of four labelled CLIP-tag or ACP-tag fusion proteins, 425(scFv)CLIP-
488 (1), 425(scFv)ACP-488 (2), ACP-EGF-488 (3) and CLIP-EGF-488 (4) after small scale batch purification with 
Ni-NTA (2.2.3.2). The labelled proteins were visualized in the gel with UV transilluminator (2.2.3.1). The signal 
from ACP-EGF-488 (3) is weak but detectable. B) FACS analysis of A431 target cells and L540 negative control 
cells after incubation with the labelled fusion proteins 425(scFv)ACP-488 and 425(scFv)CLIP-488 (2.2.4.1). C) 
FACS analysis of A431 cells and L540 cells after incubation with CLIP-EGF-488 and ACP-EGF-488.  
 
3.1.7 Biotinylation via the SNAP-tag 
Analogous to the labelling with fluorophores 425(scFv)SNAP and SNAP-CD30L were 
biotinylated using a benzylguanine derivative of biotin to exploit if the SNAP fusions can be 
combined with the broad variety of available avidin/streptavidin reagents. Figure 9 shows a 
FACS analysis of both biotinylated ligands binding to their respective target cell lines and 
detected with StreptavidinDyLight488. 
 
 
Figure 9: Binding analysis of biotinylated 425(scFv)SNAP and SNAP-CD30L on target and control cells 
A431 cells (EGFR+) and L540 cells (CD30+) were incubated with approximately 1 µg/ml of biotinylated 
425(scFv)SNAP or SNAP-CD30L (2.2.3.3) for 30 min on ice and analysed by flow cytometry (2.2.4.1) 1µg/ml 
StreptavidinDyLight488 was used to detect the biotinylated fusion proteins. Left: A431 and L540 cells after 
incubation with 425(scFv)SNAP-Biotin. Right: L540 cells and U937 cells after incubation with SNAP-CD30L-
Biotin. 
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3.1.8 Competitive binding of SNAP-EGF and 425(scFv)SNAP 
Competitive binding analyses were performed to investigate if the EGFR specific probes 
SNAP-EGF and 425(scFv)SNAP could be used in parallel, e.g. in a setup where targeting for 
a therapeutic purpose shall be combined with independent targeting for molecular imaging 
(2.2.4.2). 425(scFv)SNAP inhibits binding of labelled SNAP-EGF with an EC50 value of 82 
nM. For SNAP-EGF only slight inhibition of 425(scFv) binding is observed with approx. 40 % 
decreased binding at the highest EGF concentration tested (1000 nM= 28 µg/mL). 40 % 
inhibition of EGF binding is reached at 62 nM 425(scFv)SNAP (Figure 10). 
 
 
Figure 10: Competition analysis of 425(scFv)SNAP and SNAP-EGF 
A) A431 cells were incubated with decreasing amounts of 425(scFv)SNAP (830-0.83 nM) for 30 min on ice, 
before addition of 0.0125 nM SNAP-EGF labelled with BG-505 (2.2.3.3). The fluorescence intensity on the cells 
was analysed by flow cytometry (2.2.4.1) normalized and plotted as % binding against the concentration of 
competitor (2.2.4.2). Decreasing amounts of competing 425(scFv)SNAP result in an increasing SNAP-EGF-505 
signal with an EC50 value of 82 nM. B) shows the same experiment but with SNAP-EGF as competitor and 
425(scFv)SNAP labelled with BG-505. 40% inhibition of 425(scFv)SNAP-505 binding is reached with the highest 
concentration of SNAP-EGF (1000nM). 
 
3.2 Internalization of 425(scFv)SNAP by L3.6pl cells 
The EGF-receptor internalizes rapidly upon binding of EGF. In order to analyse the 
internalization behaviour of the 425 antibody fragment, 425(scFv)SNAP was labelled with 
BG-green incubated with L3.6pl cells at 4°C or 37°C and analysed by confocal microscopy 
(Figure 11 A). The antibody-receptor complex is internalized within approximately 1 h at 37 
°C but not at 4 °C, leading to accumulation of fluorescence inside the cells. The formation of 
endosomal structures is clearly visible. The nucleus was stained with Draq5. Figure 11 B 
shows binding and internalization of 425(scFv)SNAP by GFP transfected L3.6pl-GFP cells. 
Here the AlexaFluor 647 dye was used to enable parallel detection of GFP. The probe shows 
membrane staining and some internalization while the GFP signal is distributed 
homogenously in the cells. 
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Figure 11: Internalization of the 425(scFv)SNAP-488/EGF-receptor complex by L3.6pl cells 
A) L3.6pl cells were incubated with BG-488 labelled 425(scFv)SNAP (green signal) (2.2.3.3) for up to 60 min on 
ice or at 37°C. Binding/internalization of the fusion protein was analysed by confocal microscopy (2.2.5). Draq5 
was used to counterstain the nucleus (blue). 425(scFv)SNAP-488 accumulates over time in intracellular vesicles 
at 37°C but not at 4°C. B) maxGFP transfected L3.6pl cells (2.2.4.4) were incubated with 425(scFv)SNAP labelled 
with AlexaFluor647. The maxGFP signal (1), the 425(scFv)SNAP-AlexaFluor647 signal (2), a transmitted light 
picture (3) and the overlay of 1-3 (4) are shown. 
 
3.3 Coupling of oligonucleotides to SNAP-tag fusion proteins 
Synthetic siRNA molecules and DNA oligonucleotides were modified with BG in order to test 
if the coupling methodology is applicable to this class of molecules as well. siRNA molecules 
were successfully coupled to 425(scFv)SNAP, Ki4(scFv)SNAP or SNAP-EGF with coupling 
efficiencies of up to 85% modified protein, as analysed by gel shift analysis using SDS-
PAGE. Various experiments were performed to analyse if the coupled siRNA is capable of 
inducing RNA interference in targeted cells. However, despite efficient coupling, siRNA 
activity could not be demonstrated in a reproducible manner. The results of these 
experiments are therefore not presented here. 
The coupling of DNA oligonucleotides for the use as a specific detection system for 
complementary nucleotides was analysed in collaboration with the group of Prof. Niemeyer 
(Chemical Biology, TU-Dortmund). A BG-modified DNA oligo was coupled to Ki4(scFv)SNAP 
and detected with a complementary oligo chemically attached to streptavidin/Biotin-Atto647. 
Specific binding of Ki4(scFv)SNAP-oligo to L540 cells and detection via the coupled oligo 
could be demonstrated by flow cytometry and confocal microscopy (Figure 12). 
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Figure 12: Ki4(scFv)SNAP coupled to a benzylguanine modified DNA oligo-nucleotide 
Ki4(scFv)SNAP was conjugated with a BG modified DNA oligo-nucleotide (2.2.8) and 1 µg of protein was 
incubated for 20 min on ice with L540 target cells or control cells. Binding of the conjugate was analysed by flow 
cytometry (2.2.4.1) and confocal microscopy (2.2.5). The coupled oligonucleotide was detected with a 
complimentary nucleotide sequence chemically conjugated to streptavidin that was labelled with biotin-Atto647 
(red). A) FACS analysis of L540 and L3.6pl cells after incubation with the Ki4(scFv)SNAP-oligo conjugate or 
controls. B) Confocal microscopy analysis of the same cells used for flow cytometry. 
 
3.4 Coupling SNAP-tag fusion proteins to luminescent silica 
beads 
To test the versatility of the SNAP-tag mediated coupling procedure, carboxyrhodamine-
labelled silica beads were modified with an N-hydroxysuccinimideester derivative of BG (BG-
GLA-NHS) via surface amino groups (provided by Dr. Carsten Gellermann, Fraunhofer ISC). 
The anti-CD30 scFv Ki4 was coupled to these beads, and the labelling and binding 
properties were analyzed by flow cytometry (data not shown) and confocal microscopy 
(2.2.4.3 and 2.2.6.1). The bead conjugates showed specific labelling of CD30+ L540 cells 
(Figure 13 A) while only minimal background was observed when the SNAP-tag was blocked 
previously with bromothenylpteridine (Figure 13 B). No binding of the beads was observed 
on CD30- U937 cells (not shown). The beads were coupled in a ratio of approx. 5 
ligands/bead and, as a result of the expected multivalency, the formation of cell aggregates 
was observed, where several cells were linked together by the beads.  
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Figure 13: Confocal microscopy of Ki4(scFv)SNAP modified fluorescent silica beads on L540 cells 
Fluorescent silica beads were modified with BG and Ki4(scFv)SNAP was coupled to the beads via the SNAP-tag 
(2.2.6.1). Bead conjugates were incubated with L540 cells for 30 min on ice and binding to the cells was analysed 
by confocal microscopy (2.2.5). (A) L540 cells after incubation with Ki4(scFv)SNAP-coupled beads. The signal 
from the silica beads is shown in red. The nucleus was stained with Draq5 (blue). (B) L540 cells incubated with a 
Ki4-SNAP/bead preparation where the SNAP-tag was previously blocked with bromothenylpteridine. In each 
panel, 1) signal from carboxyrhodamine silica beads, 2) nucleus stained with Draq5, 3) transmitted light picture, 
and 4) overlay of 1-3.  
 
3.5 Coupling of SNAP-tag fusion proteins to Polyglycerol 
Doxorubicin Conjugates 
The targeted delivery of polymer-drug conjugates is an active area of research and the 
conjugation of a polymeric drug compound with the targeting ligand can be challenging. In 
order to see if the SNAP-tag technology can be used for coupling of a targeting ligand, 
branched polyglycerol scaffolds (PG) of approximately 10 kDa MW containing three 
equivalents of Doxorubicin/particle (PG-Doxo) were modified with benzyl guanine. Different 
particles were synthesized by a collaboration partner (Dr. Marcelo Calderon, Institute for 
Chemistry and Biochemistry, FU-Berlin) and coupling of Ki4(scFv)SNAP and 
425(scFv)SNAP was analysed by SDS-PAGE, flow cytometry and confocal microscopy. The 
particles could be successfully conjugated via the SNAP-tag. The amount of coupling was 
analysed by SDS-PAGE by band shift assay combined with spectral unmixing of the 
fluorescent signals from Doxorubicin, ICC/ITCC and vista green that was added to detect 
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unoccupied SNAP-tag (Maestro software, CRi). Exact quantification of the coupling efficiency 
was not possible with this assay but the added scFvSNAP was completely occupied with 
polymer-bound BG when incubated in a ratio of 1 to 1.9 (SNAP/BG). 
Binding of Ki4(scFv)SNAP conjugated with PG containing Doxorubicin and indocarbocyanine 
(ICC, a CY3 analogue) is shown in Figure 14. 425(scFv)SNAP conjugated to the same 
particles efficiently binds on A431 cells and is internalized when incubated at 37 °C but not at 
4 °C. Particles not containing benzyl guanine were incubated with the ligands in parallel and 
used as a control for specific coupling. At 37 °C the not conjugated PG-Doxo particles are 
taken up by A431 cells to some extend while no binding or attachment is observed at 4 °C 
(Figure 14 C+D). The cytotoxic activity of the free PG-Doxo particles was analysed on A431 
and L3.6pl cells in a XTT cell viability assay. IC50 values ranged between 2-3.2 µM on A431 
cells and 0.44-0.51µM on L3.6pl cells. The cytotoxicity of PG-Doxo-BG-ITCC conjugated to 
425(scFv)SNAP on A431 cells was compared with unconjugated PG-Doxo-BG-ITCC. The 
conjugated sample exhibited a slightly lower IC50 value than the free drug-polymer (not 
shown). 
 
 
Figure 14: 425(scFv)SNAP conjugated to PG-Doxo-ICC-BG nanoparticles 
425(scFv)SNAP was conjugated to PG-Doxo-ICC-BG or the same particle without benzylguanine (2.2.6.2). The 
conjugates were analysed by confocal microscopy (2.2.5) and by flow cytometry (2.2.4.3) after incubation with 
A431 cells at 4 °C or 37 °C. The ICC signal is shown in red, the nucleus was stained with Draq5 (blue). A) A431 
cells after incubation with 425(scFv)SNAP-PG-Doxo-ICC at 4 °C. B) A431 cells after incubation with 
425(scFv)SNAP-PG-Doxo-ICC at 37 °C. C) A431 cells after incubation with PG-Doxo-ICC at 4 °C. D) A431 cells 
after incubation with PG-Doxo-ICC at 37 °C. E) Analysis by flow cytometry of the same cells used in A + C. F) 
Analysis by flow cytometry of the cells used in B + D. 
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3.6 SNAP fusion proteins for in vivo optical imaging 
3.6.1 Experimental setup 
In order to evaluate if the scFvSNAP fusion proteins can be used as optical imaging probes 
that target tumour cells in vivo, the EGFR specific single chain antibody fusion 
425(scFv)SNAP was labelled with the NIR dye BG-747 and administered to mice bearing 
subcutaneous L3.6pl-GFP tumours. The accumulation of the labelled antibody at the tumour 
site was monitored with the Maestro system by taking pictures of the whole mouse over a 
period of 72 h at defined time points. The CD30 specific Ki4(scFv)SNAP-747 was used as a 
non tumour targeting probe. To verify that the accumulation of fluorescence in the tumour is 
a result of specific binding to the target receptor, a competition experiment was performed by 
administration of a 20 fold molar excess of unlabelled 425(scFv)SNAP prior to the injection of 
the labelled probe. In a 4th group of mice the EGFR specific full-length antibody C225 
(Cetuximab) labelled with an NHS-ester derivative of the 747 dye, was injected to compare 
the targeting efficiency and kinetics of this bivalent 150 kDa antibody with the monovalent 50 
kDa antibody fragment. Table 14 summarizes the experimental setup.  
 
Table 14: In vivo optical imaging with 425(scFv)SNAP-747 and control groups 
(r.o.=retro orbital injection, s.c.=subcutaneous ) 
 
3.6.2 Verification of labelling and binding activity before administration in 
vivo 
Labelling and binding properties of the probes were analysed shortly before administration to 
the mice. The SNAP-tag probes had a labelling efficiency of >90 % and the dye to protein 
ratio determined for the C225-747 was 2.7 to 1. The labelled imaging probes were separated 
by SDS-PAGE under reducing conditions and the Dy-747 fluorescence was visualized with 
the Maestro system (Figure 15 A) before the gel was stained with Coomassie brilliant blue 
Group (mice, n=4) Imaging probe (nmol/mouse, r.o.) Tumour (s.c.) time range 
1 425(scFv)SNAP-747 (0.5 nmol, 25 
µg) 
L3.6pl-GFP pre + post injection, 10 h, 24 
h, 48 h, 72 h 
2 Ki4(scFv)SNAP-747 (0.5 nmol, 25 
µg) 
L3.6pl-GFP pre + post injection, 10 h, 24 
h, 48 h, 72 h 
3 unlabelled 425(scFv)SNAP (10 nmol, 
500 µg) + 425(scFv)SNAP-747 (0.5 
nmol, 25 µg) 
L3.6pl-GFP pre + post injection, 10h, 24h, 
48h, 72h 
4 C225 labelled with Dy-747-NHS (0.25 
nmol, 37.5 µg) 
L3.6pl-GFP pre + post injection, 10 h, 24 
h, 48 h, 72 h, 96 h, 120 h, 
(144 h) 
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(Figure 15 B). The picture shows that the three probes are well labelled and of high purity. 
Figure 16 illustrates the binding activities of 425(scFv)SNAP, Ki4(scFv)SNAP and C225 as 
measured by flow cytometry. In A, the 425(scFv)SNAP probe labelled with BG-
AlexaFluor647 shows strong binding to L3.6pl cells. Ki4(scFv)SNAP shows only minimal 
background signal. B + C show binding of the 747 labelled 425(scFv) and Ki4(scFv) probes 
prepared for the in vivo application on target and non target cells. These probes were 
detected with a secondary antibody because the NIR label cannot be measured with the 
FACS Calibur flow cytometer. The activity and specificity of both probes could be confirmed. 
The AlexaFluor647 label was further used to verify the binding of 425(scFv)SNAP on the 
GFP transfected L3.6pl cells. The dye is detected in FL-4 and can therefore be used in 
parallel with GFP, which is measured in FL-1 but can also be detected in FL-2 and FL-3. The 
signal intensities on the transfected and the non-transfected cells are almost identical (Figure 
16 A+D).  
 
 
Figure 15: SDS-PAGE of the 747-labelled probes 
Approximately 5µg of each probe labelled with BG-747 or Dy-747 for the application in vivo (2.2.3.3 + 2.2.3.4) 
was separated by SDS-PAGE (2.2.3.1). The stained proteins were visualized with the Maestro system using the 
deep red filter set (A) and by coomassie staining of the same gel (B). 1) Heavy and light chain of C225-747, 2) 
Ki4(scFv)SNAP-747 and 3) 425(scFv)SNAP-747.  
 
3.6.3 The L3.6pl-GFP subcutaneous tumour model 
L3.6pl-GFP cells (2.2.4.4) were injected subcutaneously into nude mice and tumours grew to 
3-4 mm diameter within 6 days with a take rate of 100 %. The tumour growth was monitored 
by means of the GFP fluorescence. At all time points the GFP fluorescence allowed precise 
localization of the tumour cells and also the co-localization of the tumour with the targeted 
fluorescence signal. Cells could be detected immediately after the injection with numbers as 
low as 2x105 cells. Visual inspection of excised tumours confirmed a strong vascularization. 
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Figure 16: In vitro binding analysis of the 425(scFv)SNAP, Ki4(scFv)SNAP and the full-length antibody C225 
Ki4(scFv)SNAP and 425(scFv)SNAP and C225 were labelled with BG-AlexaFluor647, BG-747 or Dy-747-NHS 
(2.2.3.3 + 2.2.3.4) and 500ng of each sample was used for analysis by flow cytometry on target and control cells 
(2.2.4.1). A) 425(scFv)SNAP and Ki4(scFv)SNAP labelled with BG-Alexa647 on EGFR+ L3.6pl pancreatic 
carcinoma cells. B) Binding of the 747 labelled probes for in vivo application (detected with antiHisAlexaFluor488). 
C) Positive control for the non tumour specific probe Ki4(scFv)SNAP on L540 Hodgkin-lymphoma cells. D) 
425(scFv)SNAP-Alexa647 binding on maxGFP transfected L3.6pl cells. E+F) Dy-747 labelled and unlabelled 
C225 (Cetuximab) on L3.6pl and L540 cells. 
 
3.6.4 Distribution and tumour accumulation of the imaging probes  
The mice were anaesthetized by intramuscular injection of Ketamin/Xylazin and the imaging 
probes were administered by retro orbital injection (2.2.9.3). Images were acquired before 
(pre), immediately after the injection (post) and after 10 h - 72 h using the blue and the deep 
red filter in the multi filter acquisition mode (2.2.9.6). Exemplarily Figure 17 shows a complete 
set of images of a mouse treated with 0.5 nmol 425(scFv)SNAP-747. The white light images 
in the first row allow localization of the tumour on the left upper leg. The composite images 
display the tumour derived GFP fluorescence (green) and the targeted NIR fluorescence 
(red) with the background pseudo-coloured in gray. The GFP fluorescence can be detected 
and clearly discriminated from the background fluorescence (line three, isolated GFP signal). 
The Dy-747 signal (last line) is not detected before injection of the probe but rapidly 
distributes in the whole mouse after the injection. Accumulation in the kidneys is observed 
immediately after the injection and Dy-747 fluorescence can later be detected in the urine. 
After 10 h there is a strong signal that co-localizes with the tumour derived GFP signal. 
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Residual Dy-747 signal is found in the kidneys and at the site where the anaesthetic was 
injected, as a result of a small bleeding and accumulation of residual circulating probe. The 
Dy-747 fluorescence in the tumour decreases over 48 h and is hardly detectable after 72 h 
(not shown). After 48 h accumulation of Dy-747 fluorescence is observed in the stomach. 
This effect occurred in most mice that received a scFvSNAP probe after 24 h to 48 h but was 
usually not observed anymore after 72 h.  
 
 
Figure 17: In vivo fluorescence imaging with 425(scFv)SNAP-747 
0.5 nmol of the EGFR specific probe 425(scFv)SNAP-747 were injected retro-orbitally into a mouse bearing a 
subcutaneous L3.6pl-GFP pancreatic carcinoma xenograft (2.2.9.2) and images were acquired pre-, post- and 10-
48h after injection. Tumour derived GFP fluorescence and the probe derived 747 fluorescence were measured in 
a single acquisition step with a CRi-Maestro imaging system and unmixed with Maestro software (2.2.9.6 + 
2.2.9.7). White light images, mixed fluorescence images, the isolated GFP signal and the 747 fluorescence 
images are shown.  
 
A comparison between the tumour targeting of 425(scFv)SNAP, the non tumour specific 
probe Ki4(scFv)SNAP and 425(scFv)SNAP-747 competed with unlabelled probe is shown in 
Figure 18. Only the Dy-747 fluorescence is displayed and the pictures are representative for 
all mice in each group. The overall distribution is similar between the different probes but the 
tumour signals obtained with the EGFR specific probe were constantly higher then those 
obtained in the control groups.  
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Figure 18: Tumour targeting and accumulation of 425(scFv)SNAP-747 compared to a non targeting probe and 
competed 425(scFv)SNAP-747 
0.5 nmol of the tumour specific probe 425(scFv)SNAP-747 (upper panel) or the non specific probe 
Ki4(scFv)SNAP-747 (middle) were injected into tumour bearing mice (2.2.9.2 + 2.2.9.3) and images were 
acquired until 48 h after injection with a CRi-Maestro imaging system and unmixed with Maestro software (2.2.9.6 
+ 2.2.9.7). The bottom panel shows images of a mouse injected with a 20 fold molar excess of unlabelled probe 
prior to the injection of 0.5 nmol 425(scFv)SNAP-747. Dy-747 fluorescence is detected throughout the body right 
after injection and accumulates in the kidneys (post). A prominent signal is observed at the site of the tumour 10-
24 h post injection. After 48 h a signal is observed in the upper digestive tract of the mice. Only the unmixed Dy-
747 signal is shown. Images are displayed with optimal contrast; the signal intensity is therefore not directly 
comparable between the pictures.  
 
3.6.5 Tumour to background ratios and absolute signal intensities 
To evaluate the targeting efficacy in the different groups, tumour to background ratios (TBR) 
were built as described (2.2.9.7) for each mouse and time point.  
425(scFv)SNAP-747 gives an average peak TBR of 33.2 ± 6.3 10 h post injection. The 10 h 
TBR in the Ki4(scFv)SNAP-747 control group is significantly lower with 5.44 ± 1.92 
(p=0.029). In the competition group the 425(scFv)SNAP-747 TBR is decreased to 6 ± 1.35 
(p=0.029) (Figure 19). The highest absolute signal intensities in the "specific targeting" group 
were measured within the first 30 minutes post injection of the probes with peak values of 
160 ± 24 counts/pixel in the tumour and 103 ± 8 counts/pixel as average background at an 
exposure time of 5000 ms. Absolute signals in the tumour decreased to 71 ± 6 and 2,3 ± 
0.36 for the background after 10 h (Figure 21). 
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Figure 19: Tumour to background ratios (TBRs) obtained with the different NIR labelled imaging probes 
Groups of mice (n=4) bearing subcutaneous L3.6pl-GFP tumours (2.2.9.2) were injected with 0.5nmol imaging 
probe (2.2.9.3) and the tumour to background ratios (TBRs) were determined for each mouse and time point in 
the unmixed images acquired with the Maestro imaging system (2.2.9.7). A) Average TBRs of the EGFR specific 
probe 425(scFv)SNAP-747 compared to the non-specific probe Ki4(scFv)SNAP-747 and 425(scFv)SNAP-747 
competed with a 20x molar excess of unlabelled antibody at 0-48 h. B) TBRs 10 h post administration of the 
scFvSNAP probes. The differences between the groups were analysed for statistical significance using a Mann-
Whitney test. P values are indicated. 
 
3.6.6 Comparison of 425(scFv)SNAP and C225 optical probes  
In order to compare the kinetics and targeting properties of 425(scFv)SNAP with a well 
established therapeutic anti EGFR antibody, C225 (Cetuximab) was labelled with Dy-747-
NHS (2.2.3.4) and administered to tumour bearing mice. As shown in figure 19 strong 
accumulation in the tumour is observed after 10 h with average signal intensities approx. 10 
times higher than those of the single chain based construct (Figure 21 A+B). Tumour to 
background ratios however are significantly lower with 4.8 ± 0.4, p=0.029 (Figure 21 D). No 
renal uptake or excretion via the bile is observed for the full-length antibody. The TBR 
increases slowly from 4.8 to 8.6 ± 0.4 after 72 h. In contrast to the single chain based probe, 
the average fluorescence in the tumour increased during the first 48 h of measurement 
before reaching a plateau at around 48 h (Figure 20 + Figure 21 A). 
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Figure 20: Distribution and tumour accumulation of 425(scFv)SNAP-747 and C225-747 0-72 h post injection in 
tumour bearing nude mice 
Images were acquired with the CRi-Maestro system before and after injection of 0.5 nmol 425(scFv)SNAP-747 or 
0.25 nmol C225-747 (2.2.9.3) into mice bearing subcutaneous L3.6pl-GFP tumours (2.2.9.2). The unmixed Dy-
747 signal is shown (2.2.9.7). Dy-747 fluorescence is detected throughout the body right after injection of the 
probes (post). Accumulation of Dy-747 fluorescence at the site of the tumour is observed at 10-24 h post injection 
of 425(scFv)SNAP-747. A signal in the upper digestive tract is detected at 48 h post injection (upper panel). Dy-
747 fluorescence accumulates at the site of the tumour over 72 h in the C225-747 treated mouse (lower panel). 
The images were adjusted in order to display the broad range of signal intensities. Relative signal intensities are 
shown in the scale bar. The factor by which the signal is enhanced is indicated in the lower left of each picture. 
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Figure 21: Absolute tumour and background signals measured with C225-747 compared to 425(scFv)SNAP-747 
Groups of tumour bearing mice (n=4) were analysed with the Maestro imaging system after injection of 0.5 nmol 
425(scFv)SNAP-747 or 0.25 nmol C225-747 (2.2.9.3). The Dy-747 signal intensities and tumour to background 
ratios (TBRs) were determined for each mouse and time point in the unmixed images (2.2.9.7). A) Tumour and 
background signals in C225-747 treated mice measured over 72 h. B) Tumour and background signals in 
425(scFv)SNAP-747 treated mice measured over 48 h. C) Comparison of 425(scFv)SNAP-747 and C225-747 
signals 10 h post injection. The exposure times for image acquisition were 1000 ms for C225 and 5000 ms for 
425(scFv)SNAP. D) Tumour to background ratios 10 h post injection of the probes. The difference between the 
groups was analysed for statistical significance using a Mann-Whitney test (p<0.05).  
 
Figure 22 shows all mice analysed in the four groups 10 h post injection of the respective 
probe and illustrated as heat maps to allow visual comparison with the quantitative data 
obtained from the unmixed images. Only the 747 signal is shown and displayed 10 fold 
enhanced in the scFvSNAP groups. The tumours can be localized in most of the animals. In 
some cases an accumulation of signal is observed on the site where the anaesthetic was 
injected (M1 C225-747 and M3 Ki4(scFv)SNAP-747). A probe depot on the site of injection 
was observed occasionally in the first 30 min after injection and in rare cases persisted for up 
to 12 h (M2 Ki(scFv)SNAP-747). A slightly higher background was observed in the 
Ki4(scFv)SNAP control group compared to the 425(scFv)SNAP and the “competitive binding” 
group. 
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Figure 22: EGFR+ tumour targeting of NIR dye labelled full-length antibody and scFvSNAP-tag probes 
Heat map images of four mice per group (M1-M4), 10 h after administration of the respective imaging probe 
(2.2.9.3 + 2.2.9.6). 1st column: Dy-747-NHS labelled C225 (Cetuximab). 2nd column: EGFR specific 
425(scFv)SNAP labelled with BG-747. 3rd column: binding of 425(scFv)SNAP-747 competed with a 20x excess of 
unlabelled antibody. 4th column: non tumour specific probe Ki4(scFv)SNAP-747. The absolute signal intensities 
are 10x enhanced for the scFv based probes. 
 
3.6.7 Optical imaging using the LI-COR Pearl system 
An early series of experiments was performed with 425(scFv)SNAP labelled with BG-782 
and Ki(scFv)SNAP labelled with AlexaFluor 647 using the Pearl imaging system (LI-COR). 
After injection of 1 nmol probe, mice with subcutaneous L3.6pl-GFP tumours were imaged 
starting 30 min post injection (earlier time points were not measured due to organizational 
reasons arising from parallel measurement with the Maestro system). The tumour GFP 
fluorescence could not be measured with this system. Accumulation of 425(scFv)SNAP-782 
is observed in the kidneys as well as in the tumour on the left leg after 30 min (green signal, 
Figure 23 A). Residual signal in the kidneys is detected after 10 h along with strong 
fluorescence accumulation in the tumour. By 24 h the signal in the tumour is still bright while 
the kidney are devoid of any signal. The probe is not detectable with the used settings after 
72 h. In contrast, no specific accumulation is observed for Ki4(scFv)SNAP (Figure 23 B). 
Figure 23 C shows ventral view pictures of a mouse injected with 425(scFv)SNAP-782. 
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Signals are detected in the lower digestive tract in the 700 nm channel before the 
administration of the probe and more pronounced in the stomach 24 h post injection (Figure 
23 A+B). Accumulation of Dy-782 fluorescence is also seen in the liver as early as 10 min 
post injection and is persisting for at least 10 h. A strong signal is detected in the bladder 
after 10 h. 
 
 
Figure 23: Distribution of 425(scFv)SNAP-782 and Ki4(scFv)SNAP-647 measured with a LI-COR Pearl system 
425(scFv)SNAP was labelled with BG-782 and Ki4(scFv)SNAP was labelled with AlexaFlour 647 (2.2.3.3) and 
1nmol was injected in tumour bearing nude mice. Tumours are located on the left leg A) Distribution of 
425(scFv)SNAP-782 (green signal) monitored over 72 h with a LI-COR Pearl system (2.2.9.8). 782 fluorescence 
is detected in the kidneys 30 min post injection and at the site of the tumour until 24 h post injection. Background 
signal (red) is observed in the digestive tract. B) Distribution of Ki4(scFv)SNAP-AlexaFluor647 monitored over 72 
h (red signal). Both, AlexaFluor647 fluorescence and background fluorescence are detected in the upper 
digestive tract after 10-72 h (yellow signal). C) Ventral view of a mouse after injection of 425(scFv)SNAP-782. 782 
fluorescence (green) is detected in liver and bladder, background signal (red) is observed in the digestive tract. 
 
3.6.8 Fluorescence molecular tomography 
FMT measurements were performed in the laboratory of Prof. Kießling (University Hospital 
Aachen, Institute for Biomedical Technology in the Department of Experimental Molecular 
Imaging). 425(scFv)SNAP-747 and Ki4(scFv)SNAP-747 treated animals were analysed in 
parallel with the Maestro system at the 10h time point (2.2.8.9). Figure 24 shows 2D-images 
of the tumour specific and the non-tumour specific group. An enhanced contrast is clearly 
visible and the 2D images largely correlated with the Maestro measurements. Quantitative 
data obtained from the 3D-images, however, did not correlate with the visual impression from 
neither the 2D- nor the 3D-images. Background signals from the digestive tract could not 
always be discriminated from tumour-derived signals. 
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Figure 24: Tumour accumulation of scFvSNAP probes measured with the VisEn-FMT system 
Mice with subcutaneous L3.6pl-GFP tumours (2.2.9.2) were analysed with a VisEn-FMT system (2.2.9.9) 9 h after 
injection of 0.5 nmol of the tumour specific probe 425(scFv)SNAP-747 (upper panel) or the unspecific probe 
Ki4(scFv)SNAP-747 (lower panel) (2.2.9.3). 2D-images of the treated mice are shown. Red indicates high signal 
intensity, blue indicates low signal intensity. 
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4 Discussion 
Both molecular imaging and targeted drug delivery cover a wide range of different 
approaches. They, however, have in common the requirement of thoroughly designed 
binding probes that display high target specificity, high affinity, suitable pharmacokinetics and 
a general possibility of functional modification. The data presented in this work pertain to the 
broad field of tumour targeting, with special focus in on the design of antibody based affinity 
probes, their modification with different effector molecules and their use for in vivo optical 
imaging. Antibody fragments are in many respects ideal ligands that can be used in a wide 
range of tumour targeting applications, but their chemical modification is challenging. 
Functional groups that can be used to attach other molecules to proteins, amino groups on 
lysine residues, sulfhydryls on cysteines or carboxyls on aspartic and glutamic acid are in 
most cases randomly distributed throughout the protein and their non specific modification 
can have unpredictable side effects on the stability, solubility and affinity of the modified 
proteins. The most common approach for selective coupling is the introduction of cysteine 
residues at the C-terminus of the antibody fragment, which can be used e.g. for maleimide or 
disulfide exchange reactions. As the variable domains of an antibody normally contain an 
intra-chain disulfide bond, this method does not guarantee site-specific modification but it has 
been applied successfully for the formation of scFv dimers, labelling with fluorophores and 
conjugation to quantum dots [126-129]. As an alternative strategy, single chain antibody 
fragments were fused to the SNAP-tag to enable their covalent modification without impairing 
their binding properties. Fusion to the tag opens a diversity of possible applications, some of 
which have been explored in this thesis. 
 
4.1 Production and site-specific labelling of SNAP-tag fusion 
proteins 
To demonstrate the feasibility of directed coupling of protein ligands and antibodies using the 
SNAP-tag method, a series of fusion proteins was cloned and expressed containing either a 
single chain antibody fragment or a corresponding natural ligand directed against well-
characterized tumour markers. SNAP-tag fusion proteins have been described previously, 
mainly expressed intracellular as a tool in cell biology in combination with membrane 
permeable fluorescent dyes [121]. Production in E. coli, yeast and mammalian cells has been 
reported, but never with the intention of producing large amounts of a reagent for further 
applications [118, 130]. Transient expression in 293T cells provides a convenient system that 
allows rapid screening of the fusion proteins. The vector system applied contains an eGFP 
reporter gene that is co-expressed with the target protein on a bicistronic messenger RNA 
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via an internal ribosomal entry site. This way, expression of the target protein can be 
assessed directly by correlation with eGFP expression levels [123]. The yield of purified 
fusion protein was 5 -15 mg/L supernatant. For 425(scFv)SNAP up to 15 mg/L could be 
purified without further enrichment for high-performance clones, indicating that much higher 
yields should be possible. Production in CHO-K1 cells was also tested for two constructs 
(Ki4(scFv)SNAP and SNAP-EGF), but more intense screening and selection of producing 
cells was necessary and the expression levels of 293T cells were not reached. The yields 
obtained with the 293T system are sufficient for most pre-clinical applications. If larger 
amounts of a specific recombinant protein are required, the generation of stable CHO clones 
could be considered to enable the establishment of a reproducible fermentation process. 
Production yields for other SNAP-tag fusion proteins have not been published. The 
scFvSNAP proteins are purified via Ni-NTA IMAC using the C-terminal His-tag. The His-tag 
is potentially immunogenic and translation into clinical application would require alternative 
purification strategies such as ion exchange chromatography.  
All constructs analysed in this work, as well as several more that were tested until now, 
retained both the binding activity of the parental molecule and SNAP-tag activity as shown by 
flow cytometry. The fact that such activity could be demonstrated for a range of different 
ligand formats, the extracellular domain of a membrane glycoprotein (CD30L), a secreted 
peptide ligand (EGF), and engineered antibody fragments, provides evidence for the broad 
applicability of the fusion to the SNAP-tag and the production of the fusion proteins in 
mammalian cells. The tag was functional at the N- and C-terminal position of the protein, but 
no activity was seen when it was placed in between two single chain fragments as in 
425(scFv)-SNAP-425(scFv). It is likely that sterical problems influence the activity in this 
case. In fact, no SNAP-tag fusions with two fusion partners have been reported so far. 
The activity of the SNAP-tag was analysed with a series of commercially available BG 
containing fluorophores and the coupling efficiency was measured photospectrometrically. 
Nearly quantitative labelling was observed with different fluorophores and ligands indicating 
that the reaction of the tag with BG is not much influenced by the attached molecule. BG-
biotin was coupled in the same way and the SNAP bound biotin was available for interaction 
with streptavidin as demonstrated by flow cytometry. Labelling with biotin allows the 
combination with a large selection of avidin/streptavidin reagents for analysis in vitro. The in 
vivo use of avidin/streptavidin, however, is problematic because of the immunogenicity of 
these proteins.  
The CLIP-tag is, as the SNAP-tag, based on hAGT and was engineered to recognize and 
bind O(2)-benzylcytosine (BC). It works analogously to the SNAP-tag and the functionality 
when fused to an scFv or EGF was demonstrated. The combination of these two tags with 
different specificity is very attractive as it enables the selective labelling in a mixture of 
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tagged proteins. Furthermore bi-functional cross linkers containing BG and BC can be used 
to generate bivalent and bi-functional antibody molecules. Such reagents have already been 
used for the selective crosslinking of protein in cell lysates [131]. Bispecific antibodies can be 
use to attract effector cells such as cytotoxic T-cells, NK-cells and macrophages [132-134] 
and in particular antibodies recruiting cytotoxic T cells to tumours by binding to CD3 have 
demonstrated impressive effects in clinical trials [135]. Crosslinking two antibodies via the 
SNAP and CLIP-tag could be a flexible alternative to existing methods. 
Concluding, the production the SNAP fusion proteins and their conjugation with small 
molecules were very efficient. Different sorts of ligands could be expressed with high yields 
and labelled with fluorophores or biotin while preserving their binding properties. As the 
modification of a molecule of interest with benzyguanine can be done in a separate reaction, 
not requiring physiologic conditions to maintain protein activity, this system should be 
applicable to many other small molecules including cytotoxic compounds and chelating 
agents for nuclear imaging and therapy. 
 
4.2 Conjugation of scFvSNAP with nucleic acids 
siRNAs and DNA oligonucleotides were coupled to the scFvSNAP-tag fusions after chemical 
modification with BG. Coupling efficiencies of up to 85 % were reached by incubation of the 
protein with a 5-10 fold excess of modified nucleid acid (data not shown).  
The coupling of siRNA to a ligand for the selective knock down of gene expression in a 
targeted cell is a promising therapeutic approach and it has been pursued intensively in the 
recent years. siRNAs directed against copGFP and lamin a/c (LMNA) were coupled to 
425(scFv)SNAP and the binding activity of the conjugates could be confirmed. The siRNA 
activity was analysed using copGFP-transfected cells and target protein levels were 
analysed by flow cytometry (for GFP) and western blot (for LMNA). siRNA mediated knock 
down could not be demonstrated. The endosomal escape of siRNA after receptor mediated 
internalisation is a major obstacle dramatically reducing the efficiency of receptor targeted 
RNA-interference [136]. siRNAs act in the cytosol of the cell and an efficient transfer from the 
endosomes is crucial for their activity. The covalent attachment of siRNAs to the SNAP-tag 
with a non-degradable linker resulting in entrapment and degradation of the constructs in the 
endosomes and lysosomes is likely one reason why no siRNA activity could be observed. In 
most approaches that use covalent conjugates of siRNAs, the RNA is attached to the 
targeting moiety via a cleavable linker [137]. A BG linker containing a reducible disulfide 
bond was synthesized to facilitate release of the siRNA from the protein. This linker is 
currently tested in combination with a 425(scFv)SNAP ligand containing a peptide adapter 
sequence between scFv and tag (A. Hussein). This adapter can be cleaved by cathepsin in 
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the endosomes and is supposed to mediate transfer of the SNAP-tag part in to the cytosol 
via a membrane transfer peptide. Nevertheless, the trend in targeted delivery approaches for 
siRNA points toward using cationic liposomal or polymeric carriers that enable delivery of 
many siRNA molecules in one particle and at the same time protect the RNA from 
degradation [138]. Such nanoparticle-based systems can easily be combined with the 
scFvSNAP-tag technology and could be considered as an alternative to the direct siRNA 
conjugates. 
In an additional set of experiments, a DNA oligonucleotide (provided by Prof. Niemeyer, 
Chemical Biology, TU-Dortmund) was coupled to Ki4(scFv)SNAP in the same way as 
described for the siRNAs. The labelling of the SNAP-tag with DNA was demonstrated by flow 
cytometry and detection of the cell bound antibody with a complementary nucleotide 
conjugated to streptavidin. These two approaches demonstrate that nucleic acids can be 
attached efficiently to the SNAP-antibodies. Next to the targeting of nucleic acids to cells via 
specific receptors, the conjugates will be interesting for the use in bio-analytical procedures 
such as immuno-PCR [139] were antibody conjugated DNA serves as template in a PCR 
reaction leading to an exponential signal amplification and highly sensitive detection in e.g. 
diagnostic assays. 
 
4.3 Coupling of scFvSNAP to silica nanoparticles 
Silica nano-beads (Dr. Gellermann, Fraunhofer ISC) were used to analyse SNAP mediated 
coupling to nano sized particles. Nano-materials, including liposomes, iron oxide, quantum 
dots, nano-gels and more, are essential components in many drug delivery and molecular 
imaging strategies [140-143]. Encapsulation of drugs into a nanoparticle can help to reduce 
systemic toxicity and increase efficacy by increasing the local concentration of the drug [144]. 
Analogously, nanoparticles are used to enhance contrast in different imaging modalities 
[145]. Their surface modification with antibodies or peptides enables receptor specific 
targeting. The silica beads that were used as a model system were modified with BG-GLA-
NHS via surface amino groups, a chemistry that is applicable to the majority of nano-
materials used for drug delivery or imaging. The beads were incubated with Ki4(scFv)SNAP 
in an approximate ratio of five antibody molecules per bead. An exact determination of the 
number of coupled antibodies was not possible, however the formation of cell aggregates 
after incubation with the antibody modified beads indicates the presence of several ligands 
per bead, inducing cross-linking of receptors on different cells. Coupling of the antibodies 
was very specific; blocking of the SNAP-tag with BTP completely prevented binding of the 
beads to the cell surface. In these experiments, the silica beads contained approximately 320 
amino groups/particle and the use of a 60 fold molar excess of BG-GLA-NHS assumedly 
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lead to a near complete modification with BG. As a result, the beads aggregated and had to 
be sonicated in the presence of a detergent to disrupt the aggregates for homogenous 
coupling. This effect can likely be attributed to an increase in hydrophobicity on the beads 
surface through the attachment of BG and the hydrophobic nature of BG-reagents has to be 
considered in further experiments. Yet, such a high degree of functionalisation is not required 
or desired for most applications. There are several examples of scFv coupled to 
nanoparticles, via a C-terminal cysteine, by using the His-tag Ni-NTA interaction or by 
random modification of amino groups [61, 62, 146-148]. However in most approaches the 
potential loss of immunoreactivity after conjugation is not analysed. Such measurements are 
complicated by the fact that coupling stoichiometries cannot be controlled accurately when 
using random modification. The immobilisation via a histidine tag is attractive because it is 
site-specific and the coupling ratio is 1:1, but the interaction is, though of high affinity, not 
covalent and the His-tag, despite being potentially immunogenic, has been correlated with 
enhanced liver uptake of scFv conjugated particles [149]. The small single chain format 
combined with site-specific, covalent coupling and predefined coupling stoichiometry can 
circumvent most drawbacks associated with conventional scFv functionalisation methods. 
 
4.4 Coupling of scFvSNAP to PG-Doxorubicin 
Hyperbranched polyglycerol (PG) structures with covalently attached Doxorubicin (Doxo) (Dr. 
Calderon, Institute for Chemistry and Biochemistry, AG-Haag, Freie Universität Berlin) were 
conjugated to the scFvSNAP fusions 425(scFv)SNAP and Ki4(scFv)SNAP as a model for a 
polymer based, targeted drug delivery system. The Doxorubicin polymer conjugates have 
been designed to improve the pharmacokinetics of free Doxorubicin. PG-Doxo structures 
similar to those used here, demonstrated superior tolerability and anti tumour activity 
compared to free Doxorubicin [150]. Polymeric drug conjugates take advantage of the 
enhanced permeability and retention effect in tumours that is a result of high vascular 
density, enhanced vascular permeability induced by various mediators such as bradykinin, 
nitric oxide and VEGF, altered vascular architecture and impaired lymphatic clearance [151]. 
Doxorubicin was conjugated covalently to the PG-Doxo dendrimers via a pH sensitive bond 
facilitating release of the drug at the low pH in the endosomes while being stable at neutral 
pH. PG-Doxo conjugates containing ICC (red fluorescence) or ITCC (NIR fluorescence) were 
modified with an average of 2 BG groups per dendrimer and conjugated to the scFvSNAP 
proteins. BG specific coupling could be demonstrated in a gel shift assay combined with 
spectral unmixing of different fluorescence signals using the Maestro system. No coupling 
was observed with particles lacking BG. When modified with Ki4(scFv)SNAP, the conjugates 
bound specifically to L540 cells or A431 cells when 425(scFv)SNAP was attached. Intensive 
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internalization of the 425 conjugate was seen on A431 cells at 37°C but not at 4°C. Also the 
particles without conjugated ligand were taken up by the cells at 37°C, but to a lower extend. 
The uptake of the particle into tumour cells is desired as they were designed to work without 
any active targeting and receptor mediated uptake. This unspecific uptake together with a 
certain leakage of Doxorubicin from the particles, however, complicated attempts to show 
selective toxicity. Similar effects were described for an anti CD20 antibody-Doxorubicin 
polymer conjugate. In these studies, the acid labile conjugation of Doxorubicin enhanced the 
toxicity compared to antibody conjugates with cathepsin-cleavable bonds. However this 
effect was not depending on target receptor expression. The enzyme cleavable attachment 
of doxo resulted in a 8 fold decrease in IC50 on receptor positive cells vs. receptor negative 
cells but the IC50 was increased approx. 100 fold compared to free Doxorubicin [152]. 
Toxicities measured with the drug conjugates (without ligand) on A431 were higher than 
those reported for free Doxorubicin, which is in concordance with the results from other cell 
lines (M. Calderon, personal communication). L3.6pl was at least four times more sensitive to 
PG-Doxo compared to A431. In targeted delivery approaches, the cellular uptake of the drug 
compound is limited by the amount of available receptor, leading to a threshold of toxicity or 
the amount of drug per ligand that has to be reached to kill a cell. With an average amount of 
three Doxorubicin molecules per particle and IC50 values between 0.4 and 3 µM for L3.6pl 
and A431, an efficient induction of apoptosis via cell surface receptors can probably not be 
realised. Nevertheless, the drug-loaded dendrimers combined with the directed coupling of 
scFvSNAP have great potential for further development as targeted drug delivery system. In 
this regard, the modification of the particles in order to decrease the ligand independent 
uptake into cells would be desirable. If the unspecific uptake is diminished upon conjugation 
with a targeting ligand remains to be investigated. Higher drug loading or the use of 
alternative drugs with higher cytotoxic activity, such as taxol, is likely to improve the potency 
of the particles in combination with a targeting ligand. The incorporation of the fluorescent 
dye ICC enabled direct visualisation of the conjugates via confocal microscopy. The near 
infrared (ITCC) labelled conjugates are particularly interesting because they enable tumour 
treatment and parallel, real time monitoring of pharmacokinetics and biodistribution by optical 
imaging. 
In conclusion, the coupling of antibody fragments to nano-sized structures, if of particulate or 
polymeric nature, via the SNAP-tag is an easy and effective procedure that allows their 
modification for targeting purposes.  
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4.5 In vivo optical imaging 
The in vivo optical imaging studies were performed after functionality and coupling capability 
of the scFvSNAP fusion had been confirmed in vitro.  
The binding specificity in vivo and the pharmacokinetic properties of the scFvSNAP fusions 
were of particular interest regarding 1st the use as probes for optical molecular imaging and 
also other imaging modalities and 2nd the conclusions that could be drawn from these to 
other scFv fusion proteins such as immunotoxins with respect to their pre-clinical evaluation 
and optimization. 
 
4.5.1 The subcutaneous pancreatic carcinoma model 
A subcutaneous tumour model was used for the optical imaging experiments. This allows the 
visual verification of tumour growth and on the other hand facilitates the detection of tumour-
derived fluorescence. The pancreatic carcinoma cell line L3.6pl displays aggressive growth 
in nude mice and has been used also for orthotopic and disseminated tumour models and for 
EGFR directed immunotherapy [122, 153]. GFP transfected tumour cells have been a 
common tool in tumour research for many years. A variety of tumour models has been 
described that use stable GFP transfection to detect and monitor tumour growth, formation of 
metastasis or treatment [154]. GFP fluorescence has limitations regarding penetration depth 
and signal intensity. Due to intensive absorption of light in tissue in the range of 500-600nm, 
strong GFP expression is required and tumours in deeper tissues need to have a size of a 
centimetre rather than millimetres to be detected with whole animal imaging. A number of 
fluorescent proteins with emission wavelengths close to the near infrared have recently been 
described, that are an attractive alternative to GFP and other fluorescent proteins for optical 
imaging applications [155, 156]. Nevertheless, the constant enrichment of bright GFP 
expression cell populations via flow cytometry and their use for the establishment of 
subcutaneous tumours was very successful. The cells could be detected immediately after 
subcutaneous injection and the tumour growth could be monitored using the Maestro system. 
Vascularisation of the tumour mass is an essential point for tumour targeting. L3.6pl cells 
show elevated expression of several pro-angiogenic factors including VEGF, bFGF, IL-8 and 
MMP9 [122]. Strong vascularisation was observed for the L3.6pl-GFP indicated by strong 
fluorescence in the tumours immediately after injection of the labelled probes and when 
examined after excision. Vascularisation of even the small tumours used in these 
experiments has likely contributed substantially to the observed, efficient targeting of EGFR. 
In contrast, in an earlier set of experiments L540 Hodgkin-Lymphoma cells were used in 
combination with Matrigel to establish subcutaneous tumours. Tumours grew within 
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approximately 10 days to diameters close to 10 mm, however targeting of these tumours with 
a single chain antibody SNAP tag fusion directed against CD30 (Ki4(scFv)SNAP) was not 
possible because the tumours were encapsulated and appeared to be not vascularised when 
analysed after excision. A drawback of the aggressive growth of the L3.6pl cells is the fact 
that the tumours cannot be used for analysis over a longer time period. Experiments had to 
be stopped after 72- 96 h due to extensive tumour growth. In general, the characteristics of a 
tumour model have to be considered for a targeting approach and optical imaging provides a 
very efficient means analysing them. 
 
4.5.2 425(scFv)SNAP as in vivo optical imaging probe 
425(scFv)SNAP was used in combination with the subcutaneous L3.6pl-GFP tumours to 
analyse the targeting properties of the SNAP fusion proteins in vivo. Four animals per group 
were used to compare the EGFR specific probe with Ki4(scFv)SNAP as a non tumour 
specific probe. In an additional group, binding of 425(scFv)SNAP-747 was competed with a 
20 fold excess of unlabelled probe as an additional proof for receptor specific accumulation. 
425(scFv)SNAP-747 accumulated specifically in the subcutaneous xenografted tumours. The 
Dy-747 signal co-localized with the tumour derived GFP fluorescence and an approximately 
6 fold higher tumour to background ratio was observed compared with the non tumour 
specific Ki4(scFv)SNAP-747. The weak signal observed with the control antibody might be 
attributed to the enhanced permeability and retention effect [151]. The target receptor 
specific binding of 425(scFv)SNAP in the tumours is additionally confirmed by the fact that 
the binding of the labelled sample can be competed efficiently with an excess of unlabelled 
probe.  
Next to target specificity, size and functional affinity are key parameters for a targeted 
imaging probe. Size is an important factor for the capacity to penetrate tissues as well as the 
clearance-rate from circulation and non-target tissues by renal filtration [157, 158]. Tumour 
retention of a probe largely depends on its affinity to the target molecule and on the extent of 
internalization by the targeted cells [159, 160]. ScFv show rapid but limited accumulation in 
tumour tissue as, due to their small size, they are cleared from the circulation within minutes 
to hours [30, 161]. This has been demonstrated with radiolabelled antibody fragments. A 
similar clearance profile was observed for both scFvSNAP fusion proteins. Either probe 
accumulated in the kidneys immediately after injection and was subsequently detected in the 
bladder, which indicates clearance through the renal filtration. However, despite the fast 
clearance, tumour accumulation and retention of the 425(scFv)SNAP-747 probe is evidently 
sufficient to yield very high tumour to background ratios 10 h post injection, allowing for 
tumour detection and monitoring. The size increase from 28 kDa to 48 kDa, as a result of 
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fusion to the SNAP-tag, may contribute to accumulation at the tumour site due to the 
prolonged circulation time, as renal filtration of proteins is considered inversely proportional 
to their size [162]. The rapid internalisation of 425(svFv)SNAP, as demonstrated in vitro, may 
contribute additionally to the tumour retention and accumulation observed in vivo. All mice 
were put on a purified diet to avoid background fluorescence in the digestive tract, seen with 
conventional mouse feed. Nevertheless, a prominent signal is observed in parts of the 
digestive tract after 24 h-48 h. It can be speculated that this signal is caused by accumulation 
and break down of the probes in the liver and excretion via the bile. Limited accumulation of 
scFvSNAP probes in the liver was observed in the experiments. As with the C225 full-length 
antibody no such signal is observed, this could point to an scFv specific phenomenon.  
 
4.5.3 Comparison of 425(scFv)SNAP with C225 
Full-length antibodies usually display excellent tumour retention. Their large hydrodynamic 
diameter (~ 10 nm) prevents glomerular filtration, which, in combination with high serum 
stability, leads to prolonged circulation. The serum stability of IgG molecules is to a large 
extend a result of their interaction with the neonatal Fc-receptor (FcRn). The receptor is 
expressed on endothelial cell and has an important function in e.g. the transfer of IgG 
molecules from the mother to the fetus. FcRn binds IgG antibodies in the blood stream and 
after pinocytosis and protects them from degradation in endosomes [163]. This effect is 
desirable in therapeutic applications and antibodies are engineered for improved affinity of 
the Fc-part to FcRn to prolong their circulation time [164]. In imaging application such as 
radio- or optical-imaging however, it results in high background signals. The EGFR specific 
C225 has been conjugated to different NIR dyes and used successfully as optical imaging 
probe [80, 102]. Also in our experiments, targeting of L3.6pl tumours with C225 was very 
efficient. Cetuximab binds to soluble EGFR with a KD of approx. 2.7nM compared to 32.3nM 
for the 425(scFv) parental antibody [165]. Consequently, the 425(scFv) construct has a much 
lower functional affinity compared to C225, considering its monovalency and an additional 
decrease in affinity from the conversion into the scFv format. The high affinity of C225 
combined with its larger size and consequently lower renal filtration rate, explains the 
observed stronger retention in the tumour tissue. However, due to the high signal throughout 
the body, the TBR is significantly lower than that of 425(scFv)SNAP. In general, scFv as 
basis for imaging probes are considered less favourable due to their lower affinity and rapid 
clearance from blood [161, 162]. Several reports describe the use of bivalent to multivalent 
constructs to prolong circulation times and to enhance tumour retention by increasing 
functional affinity [159, 160, 166]. Fusion to serum albumin has also been shown to enhance 
circulation time and overall tumour uptake of an scFv [167]. However, for monitoring e.g 
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EGFR expression under a treatment regime, a high TBR combined with a short lasting 
signal, like described for the scFvSNAP construct, is beneficial as it allows for repeated 
measurements within a short time-frame. A recent report on an 111In labelled affibody 
molecule directed against EGFR describes superior properties as an imaging probe of a 
monovalent compared to a bivalent construct due to faster systemic clearance [103]. 
 
4.5.4 In vivo optical imaging with the LI-COR Pearl and VisEn-FMT system  
Mice treated with 425(scFv)SNAP and Ki4(scFv)SNAP were analysed by fluorescence 
molecular tomography (in the laboratory of Prof. Kießling, University Hospital Aachen) in 
parallel to the measurements with the Maestro system in order to confirm the data by an 
independent measurement and with regard to quantifying the fluorescence signals. FMT 
uses mathematical models of photon propagation in tissues and three dimensional image 
acquisition and theoretically allows exact quantification of fluorescent probes in the picomolar 
range [75]. In analogy to PET imaging, “percent of injected dose” values can be obtained 
enabling a more precise analysis of targeting efficiency. While the 2D images taken from 
several mice largely confirm the data from the Maestro system, the 3D evaluations turned out 
to be difficult due to background signals most probably arising from the digestive tract. The 
system uses laser excitation and signals cannot be separated according to different spectra 
as with the Maestro software. The relative values from the regions of interest in the 3D 
images did neither correlate with the 2D FMT data nor with the Maestro data and further 
experiments are needed to investigate how FMT can be utilized for exact signal 
quantification. A promising step toward this is the use of cells transfected with a fluorescent 
protein and parallel detection of the cell derived fluorescence as an additional verification of 
signal specificity. Detection of GFP is not possible with the FMT device used, but equipment 
for detection of proteins emitting in the red range of the spectrum, such as the Katushka 
proteins [155], is possible. The majority of publications deals with characterisation and 
optimization of FMT systems, however there are some reports describing the use of 
fluorescently labelled antibodies or peptides and their accurate quantification in vivo [168, 
169]. Even if exact quantification of the targeted signals was not possible in these 
experiments, the applicability of the scFvSNAP probes for FMT could be demonstrated and 
image acquisition protocols should be optimised in coming experiments to exploit the full 
potential of this imaging technology. 
Initial targeting experiments with 425(scFv)SNAP and Ki4(scFv)SNAP as a control were 
performed using the same model as described before and images were acquired with the LI-
COR Pearl system. The distribution of the probes and their accumulation at the tumour was 
as observed in later experiments using the Maestro system but the small groups did not 
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allow statistical validation. The dorsal and ventral images show that the scFvSNAP probes 
are excreted primarily via the kidneys, as expected due to their size, and to a certain extend 
by accumulation in the liver and most likely secretion into the bile, as confirmed in later 
experiments. 
 
4.5.5 In vivo optical imaging: concluding remarks 
Concluding, 425(scFv)SNAP was successfully used as a probe for in vivo optical imaging of 
EGFR expression. The rapid clearance through renal filtration allows measurements with 
very low background 8-10 h after administration of the probe. Tumour accumulation is EGFR 
specific as demonstrated by a non-tumour specific control and competitive binding 
experiments and the targeting properties could be confirmed by measurements with two 
alternative optical imaging devises. Through coupling of a chelating agent like DTPA or 
DOTA to 425(scFv)SNAP the probe should be applicable also in clinically more relevant 
nuclear imaging modalities like PET and SPECT.  
Potential immunogenicity of the SNAP-tag fusion proteins has to be considered if a repeated 
application, if for therapeutic or imaging purposes, is intended. The SNAP-tag is derived from 
a ubiquitously expressed human protein; however, AGT is located inside the cell and is for 
this reason not “visible” to B-lymphocytes. In addition several amino acid changes were 
introduced leading to alterations also in secondary structure. The fusion of the tag to the 
binding moiety, the site of modification with a BG-substrate as well as alterations in 
posttranslational modification as a result of recombinant expression could potentially 
influence immunogenicity. The mechanisms of immune recognition, however, are complex 
and, despite advances in the identification of potential T-cell epitopes, prediction of 
immunogenicity of recombinant proteins remains to be difficult [170, 171]. As a result, these 
factors will have to be analysed carefully for each individual protein to be further developed 
for advanced pre-clinical and clinical application. The SNAP-tag has not been used for in vivo 
application before and data on immunogenicity are therefore not available. 
Next to the direct evaluation of the scFvSNAP probes for imaging purposes, an objective of 
the study was to transfer the findings regarding the tumour model and pharmacokinetics to 
other fusion proteins of comparable size, in particular scFv based immunotoxins that are a 
major focus of the workgroup. Some aspects of the data give reason to reassess the format 
of these proteins in terms of their targeting properties. Their size, as for the SNAP-tag 
fusions, is with 50 kDa to 80 kDa, below or close to the threshold of renal filtration [158]. The 
absolute amounts of scFvSNAP in the tumour were quite low, although a quantification, e.g. 
as % of the injected dose, is not possible with fluorescence reflectance imaging. Doses 
between 0.5 and 3 % of the injected dose have been reported for radiolabeled scFvs [30, 
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161]. The same can be expected for immunotoxins of comparable size, however, as 
mentioned before, for a therapeutic approach the rapid clearance within minutes is a clear 
disadvantage. An increase in size and valency is likely to enhance tumour accumulation and 
retention, and this way efficacy of immunotoxin treatment, without dramatically impairing 
tumour penetration properties.  
As discussed, the rapid clearance of the scFvSNAP antibodies can be a great advantage 
when an imaging probe for short term monitoring and repeated measurements is needed.  
The superior properties of diabodies, minibodies and triabodies compared to the monovalent 
scFvs in terms of tumour accumulation have been demonstrated [162]. Initial experiments 
with cross-linkers containing two or three BG residues indicate that the tag system can be 
used to engineer scFv derivatives with higher valency and increased size. This will allow 
customizing scFvSNAP probes for a certain application without the need for additional 
cloning steps. 
 
4.6 Outlook 
The data presented in this work describe the use of single chain antibody fragments fused to 
the self-labelling SNAP-tag as versatile affinity probes for active tumour targeting. Coupling 
of the antibodies via the tag could be demonstrated with very different substances such as 
organic fluorescent dyes, nucleic acids, polymeric pro-drugs and solid nanoparticles of up to 
100nm diameter. Limitations regarding the substrates to be coupled have not been observed 
so far, provided that the material is amenable to chemical modification with benzylguanine. 
This fact makes the SNAP fusion proteins in principle applicable in any scenario were 
receptor specific targeting is attempted. Today, recombinant antibodies against most relevant 
tumour markers are available and they can easily be converted into a corresponding fusion 
protein. Several scFv and protein ligands have been tested and all of them remained 
functional after fusion to the tag. It would nevertheless be interesting to test additional scFv, 
and other proteins that cannot be modified chemically, in this regard. 
scFv are small, monovalent binders, and the effect of valency and size on tumour 
accumulation and retention has been discussed. The further investigation of cross-linkers 
with two or more benzylguanine residues or the combination of BG (SNAP-tag) with BC 
(CLIP-tag) would allow the use of scFvSNAP/CLIP proteins as building blocks. Here it would 
be particularly interesting to analyse if a dimeric molecule displays the expected higher 
tumour accumulation and as a result, would be more suitable for the generation of e.g. a 
direct drug conjugate. 
The conjugation of Ki4(scFv)SNAP to silica nano-beads as well as their specific binding to 
L540 cells in vitro was demonstrated. Coupling of the EGFR specific 425(scFv)SNAP to e.g. 
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superparamagnetic iron oxide particles (SPIO) would allow to assess the targeting capability 
of nanoparticles in a clinically relevant imaging modality and comparison with existing data 
on EGFR targeted MRI.  
The conjugates with the PG-Doxorubicin pro-drug should be analysed in more detail. 
Coupling and specific binding could be demonstrated, but the selective toxicity on target vs. 
non-target cells has yet to be shown. In a next step the ITCC labelled dendrimers should be 
analysed in vivo to compare targeted and non-targeted accumulation in tumour tissue. Here, 
the established subcutaneous L3.6pl-GFP tumour model could be used. An increase in 
Doxorubicin loading combined with PEG shielding of the particles should be considered and 
tested in vitro. 
Regarding the use of scFvSNAP as in vivo optical imaging probes, several aspects remain to 
be investigated. As mentioned before, the effect of size and valency should be analysed with 
either cross-linked scFvSNAP or genetically engineered bivalent molecules. The 
subcutaneous tumour model was very suitable to establish the technology, it would be very 
important however to analyse the properties of 425(scFv)SNAP in an orthotopic model of 
pancreatic cancer and first experiments to set up the mouse model have been made. Within 
this context, alternative dyes or higher dye loading should be tested to increase absolute 
signal intensities and facilitate imaging of deeper tissues. The use of small quantum dots that 
can be cleared by renal filtration could be a promising approach in this regard [172].  
Finally, the combination of 425(scFv)SNAP with a chelating agent for the use as radiotracer, 
could provide additional information about targeting properties and bio-distribution. 
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5 Summary 
The targeting of tumours on the molecular level requires, next to a “target” that is selectively 
or predominantly expressed in the tumour tissue, ligand molecules that are capable of 
binding this marker with high specificity and affinity. Such affinity probes can be used for the 
delivery of bioactive molecules, such as chemotherapeutics, as well as for the visualization of 
a tumour by combination with contrast enhancing agents. Antibodies are a natural prototype 
of a targeting ligand and today antibodies are available against most known tumour markers. 
Single chain antibody fragments (scFv) are reduced to the antigen binding variable domains 
of an antibody and are therefore ideally suited as basis for tumour targeting probes. 
However, their functional modification for molecular imaging or drug delivery purposes is 
challenging. In order to build up a platform for the site-specific modification of scFv, a series 
of fusion proteins was generated, each consisting of a single chain antibody fragment or a 
natural protein ligand directed against different tumour markers, and an engineered version 
of the human DNA repair enzyme O(6)-alkylguanine DNA alkyltransferase (AGT), known as 
SNAP-tag. The tag recognizes and binds O(6)-benzylguanine (BG) and can be used to 
couple the fusion proteins covalently with a variety of substrates which are modified with BG 
in a separate reaction. 
SNAP fusion proteins were expressed in human embryonic kidney cells (HEK-293T) and 
purified from the culture supernatant using immobilized metal ion affinity chromatography to 
capture the C-terminal His-tag. The yield of purified protein ranged between 5 mg/L for a 
construct containing the natural ligand of CD30 (SNAP-CD30L) and >15 mg/L for the EGFR 
specific single chain antibody fragment fusion protein (425(scFv)SNAP). Binding activity the 
ligands was analysed by flow cytometry after labelling the tag with a selection of 
commercially available BG-modified fluorescent dyes. Fusion of the SNAP-tag to the C-
terminus of scFvs or the N-terminus of CD30L and the epidermal growth factor (EGF) did not 
influence the binding properties of these ligands. Labelling with a BG derivative of biotin 
enabled detection of the biotinylated proteins with streptavidin and allows combination of the 
fusion proteins with the broad variety of avidin/streptavidin reagents. 
With regard to using the scFvSNAP fusions for targeted delivery and molecular imaging 
purposes, the tag mediated coupling was tested with silica nanoparticles and Doxorubicin 
loaded polyglycerol–dendrimers. The silica beads served as a model for other nanoparticles 
such as quantum dots or iron oxide particles. They were modified with BG-NHS via surface 
amino groups, a chemistry which is commonly used and applicable to most nano-materials. 
The CD30 specific Ki4(scFv)SNAP fusion protein could be coupled specifically to the beads 
via the SNAP-tag and binding of the modified beads to CD30 expressing cells was 
demonstrated by confocal microscopy. 
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The EGF receptor specific 425(scFv)SNAP was attached via the tag to BG-modified, 
polyglycerol-Doxorubicin conjugates and the binding and internalisation properties of the 
complexes were compared to non-targeted conjugates. Coupling to 425(scFv)SNAP resulted 
in strong binding of the complexes to EGFR expressing cells at 4°C and increased 
internalisation at 37 °C. Due to leakage of Doxorubicin from the polymeric carrier and 
unspecific uptake of the non targeted complexes into cells, selective toxicity could not be 
demonstrated in initial experiments. 
One major focus of this work is the use of scFvSNAP fusion proteins for near infrared optical 
imaging and the characterization of their tumour targeting properties in vivo. To this end, a 
subcutaneous pancreatic carcinoma xenograft model was established in nude mice, using 
L3.6pl cells that were beforehand stably transfected with GFP to allow detection independent 
of a targeting probe. 425(scFv)SNAP and Ki4(scFv)SNAP were labelled with the near 
infrared dye BG-747 and their biodistribution and pharmacokinetics were analysed. Due to 
their small size the scFvSNAP probes were cleared rapidly from the circulation by renal 
filtration, allowing imaging with high contrast 10h after injection. The 425(scFv)SNAP probe 
showed stronger accumulation in EGFR positive tumours than the nonspecific antibody 
Ki4(scFv)SNAP and the accumulation could be outcompeted efficiently with an excess of 
unlabeled probe. The tumour to background ratios (TBRs) in the 425(scFv)SNAP group were 
significantly higher than those in the control groups.  
In order to compare the pharmacokinetics of the scFv based constructs with a full-length 
antibody, the anti EGFR antibody C225 was labelled with Dy-747 via NHS-ester coupling and 
analysed in an additional group of mice. As expected for a full-length antibody, C225 showed 
long circulation times and strong and increasing accumulation in the tumours over 72h. 
However, due to the high systemic background, the TBRs in this group were significantly 
lower than those obtained with the 425(scFv)SNAP fusion protein. 
Concluding, a new method for the site-specific, covalent modification of recombinant 
antibody fragments could be established by fusing them to the SNAP-tag. Efficient and 
specific coupling of the fusion proteins to nanoparticles and polymer-drug conjugates could 
be demonstrated, underlining the applicability of this technology in a multitude of “drug 
delivery” and “molecular imaging” approaches. In vivo optical imaging methods were 
established and used to analyse the pharmacokinetics of an EGFR specific scFvSNAP 
fusion protein. The specific and sensitive detection of subcutaneous, EGFR positive tumours 
with this probe was demonstrated. 
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7.2 Abbreviations 
Abbreviation  Abbreviation  
A ampere M  molarity (mol/l) 
aa amino acid mA milli ampere 
AA acrylamid  mAb monoclonal antibody 
Ab  antibody MCS  multiple cloning site 
ACP Acyl carrier protein min minute(s) 
Ag antigen mL milliliter 
Amp ampicilline MRI magnetic resonance imaging 
AP alkaline phosphatase MW molecular weight 
BC O(2)-benzylcytosine NHS N-Hydroxysuccinimide 
BG O(6)-benzyguanine NIR Near infrared 
bp base pair NBT-BCIP nitro blue tetrazolium chloride/5-
bromo-4-chloro-3- indolyl 
phosphate 
BSA  bovine serum albumin ng nanogram 
°C degree Celsius  nm nanometer 
DNA deoxyribonucleic acid nt nucleotides 
dNTP deoxynucleotide triphosphate NTA Nitrilotriacetic acid 
Doxo Doxorubicin NTP nucleotide triphosphate 
DTT  dithiothreitol o.n.  over night 
DTE dithioerythritol OD optical density 
EC50 half maximal effective 
concentration 
OI optical imaging 
E. coli  Escherichia coli ori origin of replication 
EDTA ethylenediaminetetraacetic acid PAA polyacrylamid 
eGFP enhanced green fluorescent 
protein  
PAGE polyacrylamid gel 
electrophoresis  
EGF epidermal growth factor PBS phosphate buffered saline 
EGFR EGF-receptor PBST phosphate buffered saline + 
0.1% Tween-20 
ETA’  Pseudomonas exotoxin A, 
deletion mutant 
PCR  polymerase chain reaction 
et al.  et altera PG polyglycerol 
EtBr ethidium bromide pH negative log of the concentration 
of hydrogen ions in solution 
EtOH ethanol PI propidium iodide 
FACS fluorescence-activated cell 
sorting 
PO peroxidase 
Fc fragment cristalizable RNA ribonucleic acid 
FITC fluorescein isothiocyanate rpm rounds per minute 
FSC forward scatter rt room temperature 
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Abbreviation  Abbreviation  
g relative centrifuge force SDS sodium dofecylsulfate 
g gram (mass unit) SEC size exclusion chromatography 
h hour scFv single chain Fv 
hAGT human 0(6) alkylguanine DNA 
alkyltransferase 
sec. second 
His-tag polyhistidine motif Taq Thermus aquaticus 
HRPO  horse radish peroxidase TAE trisacetate EDTA buffer 
IC50 half maximal inhibitory 
concentration 
Tris tris(hydroxymethyl)aminomethan
e 
ICC indocarbocyanine Tween 20 polyoxyethylene (20) sorbitan 
monolaurate 
Ig immunglobulin  U unit 
Ig leader secretory leader sequence of the 
Ig kappa light chain 
US Ultra sound 
IMAC  immobilized metal ion affinity 
chromatography 
UV  ultraviolet 
IRES internal ribosomal entry site V  volt 
ITCC indotricarbocyanine v/v volume per volume 
IVS synthetical intron w/v  weight per volume 
Kan kanamycin XTT sodium3’-[1-
(phenylaminocarbonyl)-3,4-
tetrazolium]-bis(4-methoxy-6-
nitro)benzenesulfonic acid 
hydrate 
kb kilobase β-MeSH β-mercaptoethanol 
kDa kilo Dalton   
 
7.3 One letter code of amino acids 
 
A alanine I isoleucine R arginine 
C cysteine K lysine S serine 
D aspartic acid L leucine T threonine 
E glutamic acid M methionine V valine 
F phenylalanine N asparagine W tryptophan 
G glycine P proline Y tyrosine 
H histidine Q glutamine   
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7.3 Sequences 
Nucleotide and amino acid sequence are exemplarily shown for 425(scFv)SNAP-tag and 
SNAP-EGF. Relevant restriction sites are indicated. 
 
7.3.1 425(scFv)SNAP 
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7.3.2 SNAP-EGF 
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